CTLA4 LIGAND, LINKER, CONTAINER OR INJECTION DEVICE, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHODS FOR

专利摘要:
ctla4 ligands. the present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. these molecules have been modified in order to reduce the incidence of binding by pre-existing antibodies in the bodies of an individual administered such a molecule. methods are provided for enhancing the immune response, treating cancer and/or treating an infectious disease with such molecules.
公开号:BR112018009972B1
申请号:R112018009972-4
申请日:2016-11-17
公开日:2021-08-24
发明作者:Juha Punnonen；Maribel Beaumont；Marie-Ange Buyse；Carlo Boutton；Bruno DOMBRECHT；Bjorn Victor；Robert A. Kastelein
申请人:Merck Sharp & Dohme Corp；
IPC主号:

专利说明:

[001] This application claims the benefit of Provisional Patent Application No. U.S. 62/257,001 filed November 18, 2015, which is incorporated herein by reference in its entirety.
[002] A computer readable format amino acid/nucleotide sequence listing is incorporated by reference in its entirety. The file containing the Sequence Listing is a 100kbyte ASCII text file created on November 15, 2016, named "24237WOPCTSEQ". field of invention
The present invention relates, in part, to amino acid and polypeptide sequences that bind to the T lymphocyte associated cytotoxic protein 4 ("CTLA4"), e.g., human CTLA4. In particular, the present invention relates, in part, to improved single heavy chain immunoglobulin variable domains (also referred to herein as "ISVs" or "ISVDs") binding to CTLA4, as well as proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs. Other aspects, embodiments, features, uses and advantages of the invention will be apparent to the person skilled in the art based on the invention herein. Background of the invention
[004] The knockdown of immune regulatory molecules such as cytotoxic T lymphocyte antigen 4 (CTLA-4) represents a new and promising strategy to induce tumor regression, stabilize disease and prolong survival by manipulating the immune system. An anti-CTLA-4 antibody, ipilimumab, is currently being sold for indications including melanoma. Evidence of tumor regression with prolonged time to progression was seen in melanoma patients who received CTLA-4 antibodies, and durable responses have been observed with ipilimumab in patients with melanoma, ovarian cancer, prostate cancer, and renal cell cancer .
[005] The complete activation of T cells requires two signals. The first is initiated by the T cell receptor that binds to tumor associated antigens presented by antigen presenting cells (APCs) through major histocompatibility complexes I and II. The second signal is generated when the main costimulatory receptor on the T cell, CD28, binds to B7 ligand subtypes CD80 and CD86 on the APC. The resulting dual signaling induces changes that include T cell proliferation and cytokine release, triggering and then amplifying the immune response. In response to T cell activation, CTLA-4 is up-regulated and competes with CD28 for the binding of CD80 and CD86 on APCs, but with significantly greater affinity, therefore, for T cell down-regulation—or inactivation—(Figure 1). CTLA-4, therefore, down-regulates T cell responses and APC function, resulting in a diminished immune response to tumor-associated antigens and immune tolerance.
[006] The mechanisms through which CTLA4 and PD1 exert their inhibitory effects on T cell activation are multifaceted. CTLA4 works primarily to limit T cell activation and clonal expansion, whereas PD1 works primarily to limit effector T cell function in peripheral tissues. Their distinct molecular structures, regulation, signaling pathways, ligand distribution and function in Tregs and other immune cells suggest that the combined therapeutic blockade of CTLA4 and PD1 could synergize to mediate anti-tumor immunity. Intlekofer & Thompson, J. Leuko. Biol. 94(1): 25-39 (2013); Hurwitz et al. Proc. Natl. Academic Sci. USA 95: 1006710071 (1998); Parry et al. Mol. Cell. Biol. 25(21): 9543-9553 (2005); Callahan et al. Front. Oncol. Vol 4, Art. 385 (2015).
[007] A method by which negative regulation mediated by CTLA4 is inhibited is by interfering with its interaction with its ligands by binding them to a Nanobody. There is a possibility that Nanobodies, which originate in llamas, could cause an unwanted anti-drug immune response, for example, through the binding of the Nanobodies by pre-existing antibodies in the patient's serum. Thus, the innovative methods through which Nanobodies are humanized in order to reduce or eliminate such a response are particularly valuable as are the Nanobodies that are created by such methods. Invention Summary
The present invention provides a single multispecific immunoglobulin variable domain (ISVD) as a Nanobody that binds to human CTLA4 by contacting human CTLA4 at one or more of the following VRVTVL residues (amino acids 33 to 38 of SEQ ID NO: 110), ADSQVTEVC (amino acids 41 to 49 of SEQ ID NO: 110) and CKVELMYPPPYYLG (amino acids 93 to 106 of SEQ ID NO: 110), for example, all three sites. For example, the ligand protects the residues against hydrogen-deuterium exchange in the presence of a deuterium source such as D2O. In one embodiment of the invention, the ISVD binds to human CTLA4 and generates a heat binding map (eg, as generated in a hydrogen-deuterium exchange assay) essentially as shown in Figure 13.
The present invention also provides a CTLA4 linker comprising one or more (for example 2) unique immunoglobulin variable domains (ISVDs) that bind to human CTLA4 comprising: CDR1 comprising the amino acid sequence FYGMG (amino acids 6) to 10 of SEQ ID NO: 2) or GGTFSFYGMG (SEQ ID NO: 2); CDR2 comprising the amino acid sequence DIRTSAGRTYYADSVKG (SEQ ID NO: 3) or DIRTSAGRTY (amino acids 1 to 10 of SEQ ID NO: 3); CDR3 comprising the amino acid sequence EXSGISGWDY (SEQ ID NO: 4); optionally, wherein the ISVD comprises a mutation at residues 11 and 89 (for example L11V and/or V89L, for example (E1D, L11V, A14P, Q45R, A74S, K83R, V89L, M96P, Q108L) wherein said numbers of residue are Kabat residue numbers.
The present invention provides a CTLA4 linker (for example an ISVD, for example a Nanobody) comprising CDR1, CDR2 and CDR3 of an immunoglobulin comprising the amino acid sequence shown in SEQ ID NO: 1, wherein said CTLA4 linker comprises at least one mutation with respect to the amino acid sequence shown in SEQ ID NO: 1, wherein said at least one mutation is at a position selected from the group consisting of 11, 89, 110 and 112, wherein said positions are numbered according to Kabat; and optionally including any number of additional mutations that are set forth herein or otherwise, for example up to 10 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) additional mutations (eg point mutations, substitutions, deletions, insertions). For example, in one embodiment of the invention, CDR1 comprises the amino acid sequence: FYGMG (SEQ ID NO: 2) or GGTFSFYGMG (SEQ ID NO: 5); CDR2 comprises the amino acid sequence: DIRTSAGRTYYADSVKG (SEQ ID NO: 3) or DIRTSAGRTY (SEQ ID NO: 6); and CDR3 comprises the amino acid sequence: EMSGISGWDY (SEQ ID NO: 4). For example, in one embodiment of the invention, the CTLA4 linker has a mutation with respect to SEQ ID NO: 1, wherein the amino acid residue at position 11 is chosen from L or V; the amino acid residue at position 89 is suitably chosen from T, V or L; the amino acid residue at position 110 is suitably chosen from T, K or Q; and/or the amino acid residue at position 112 is suitably chosen from S, K or Q; for example, where the mutation is 89T; 89L in combination with 11V; 89L in combination with 110K or 110Q; 89L in combination with 112K or 112Q; 89L in combination with 11V and 110K or 110Q; 89L in combination with 11V and 112K or 112Q; 11V in combination with 110K or 110Q; and/or 11V in combination with 112K or 112Q. In one embodiment of the invention, the mutation at positions 11, 89, 110 and/or 112 is as shown in Table B. In one embodiment of the invention, the CTLA4 linker further comprises one or more mutations, with respect to SEQ ID NO: 1, at positions 1, 14, 45, 74, 83 and/or 108. In one embodiment of the invention, the CTLA4 linker has a C-terminal extension of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids. For example, in the embodiment of the invention, the C-terminal extension has the formula -X(n), where X and n are as set out below: (a) n = 1 and X = Ala; (b) n = 2 and each X = Ala; (c) n = 3 and each X = Ala; (d) n = 2 and at least one X = Ala (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); (e) n = 3 and at least one X = Ala (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); (f) n = 3 and at least two X = Ala (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); (g) n = 1 and X = Gly; (h) n = 2 and each X = Gly; (i) n = 3 and each X = Gly; (j) n = 2 and at least one X = Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); (k) n = 3 and at least one X = Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); (l) n = 3 and at least two X = Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); (m) n = 2 and each X = Ala or Gly; (n) n = 3 and each X = Ala or Gly; (o) n = 3 and at least one X = Ala or Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid); or (p) n = 3 and at least two X = Ala or Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid). For example, in one embodiment of the invention, the C-terminal extension is A, AA, AAA, G, GG, GGG, AG, GA, AAG, AGG, AGA, GGA, GAA or GAG. The present invention includes a CTLA4 linker (e.g. an ISVD such as a Nanobody) which comprises an amino acid sequence of at least 85% (e.g. 85, 86, 87, 88, 89, 90, 91, 92, 93 , 94, 95, 96, 97, 98, 99, 99.5, 99.9 or 100%) sequence identity with the amino acid sequence shown in a member selected from the group consisting of SEQ ID NOs: 8 to 43, wherein the CTLA4 or ISVD linker comprises CDR1, CDR2 and CDR3 of an immunoglobulin comprising an amino acid sequence shown in SEQ ID NO: 1, wherein said CTLA4 or ISVD linker comprises at least one mutation with respect to amino acid sequence shown in SEQ ID NO: 1, wherein said at least one mutation is at a position selected from the group consisting of 11, 89, 110 and 112, wherein said positions are numbered according to Kabat . The present invention also provides a CTLA4, ISVD, Nanobody or polypeptide linker comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 9 to 40. The present invention also provides a multispecific linker comprising a CTLA4 binding moiety (eg, an ISVD such as a Nanobody) that binds to CTLA4 that binds to one or more molecules that bind to an epitope that is not the epitope to which the CTLA4 binding moiety binds (eg, PD1, CTLA4, LAG3, BTLA and/or CD27).
The present invention also provides any such CTLA4 linker, polypeptide, single immunoglobulin variable domain (ISVD) or multispecific linker that is in association with an additional therapeutic agent.
[0012] The present invention also provides an injection container or device (e.g., syringe and hypodermic needle) comprising CTLA4 linker, single immunoglobulin variable domain (ISVD), Nanobody, polypeptide or multispecific linker optionally in association with a additional therapeutic agent.
[0013] The present invention also provides a polynucleotide encoding the CTLA4 linker, single immunoglobulin variable domain (ISVD), Nanobody, polypeptide or multispecific linker, for example, which is in a vector. The present invention also provides a host cell (e.g., a CHO cell or Pichia cell) that comprises the polynucleotide or vector.
The present invention also provides a method for making a CTLA4 linker, single immunoglobulin variable domain (ISVD), Nanobody, polypeptide or multispecific linker comprising introducing a polynucleotide encoding the CTLA4 linker, single immunoglobulin variable domain (ISVD) ), Nanobody, polypeptide or multispecific ligand in a host cell (for example, a CHO cell or Pichia cell) and culturing the host cell in a medium under conditions favorable for the expression of said immunoglobulin from said polynucleotide and, optionally, purifying the immunoglobulin from said host cell and/or said medium. Any single immunoglobulin variable domain (ISVD), Nanobody, polypeptide, multispecific linker or CTLA4 linker produced by such a method.
[0015] The present invention also provides a method for preventing CTLA4 on a T cell from binding to CD80 and/or CD86 on an antigen presenting cell comprising contacting said CTLA4 with a single immunoglobulin variable domain (ISVD), Nanobody, polypeptide, multispecific linker or CTLA4 linker optionally in association with an additional therapeutic agent. The present invention also provides a method of enhancing an immune response in the body of an individual which comprises administering an effective amount of a single immunoglobulin variable domain (ISVD), Nanobody, polypeptide, multispecific linker or CTLA4 linker to the individual (e.g., mammal such as a human) optionally in association with an additional therapeutic agent. The present invention also provides a method of treating or preventing cancer or an infectious disease in the body of a subject which comprises administering an effective amount of a single immunoglobulin variable domain (ISVD), Nanobody, polypeptide, multispecific linker or CTLA4 linker optionally in association with an additional therapeutic agent to the individual. In one embodiment of the invention, the cancer is metastatic cancer, a solid tumor, a hematologic cancer, leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, breast cancer squamous cell, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid kidney tumor, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, acoustic neuroma, a primitive neuroectodermal tumor , medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelofibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer or liver cancer, breast cancer or gastric cancer. In one embodiment of the invention, the infectious disease is a bacterial infection, a viral infection or a fungal infection. For example, in one embodiment of the invention, the subject is administered an additional therapeutic agent or therapeutic procedure in association with a single immunoglobulin variable domain (ISVD), Nanobody, polypeptide, multispecific linker or CTLA4 linker.
[0016] The present invention provides a CTLA4 linker (e.g., a multivalent linker) comprising a single immunoglobulin variable domain (ISVD) that binds to human CTLA4 by contacting human CTLA4 at one or more of the following residues: VRVTVL (amino acids 33 to 38 of SEQ ID NO: 110), ADSQVTEVC (amino acids 41 to 49 of SEQ ID NO: 110) and CKVELMYPPPYYLG (amino acids 93 to 106 of SEQ ID NO: 110); wherein the ISVD comprises a mutation at residues 11 (for example L11V) and 89 (for example V89L), wherein said residue numbers are Kabat residue numbers.
The present invention also provides a CTLA4 linker (e.g. a multivalent linker) comprising a single immunoglobulin variable domain (ISVD) which binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 1, but comprising one or more mutations at a position selected from the group consisting of E1, L11, A14, Q45, A74, N73, K83, V89, M96 or Q108L (eg E1D, L11V, A14P, Q45R, A74S, N73X ( wherein X is S, V, G, R, Q, M, H, T, D, E, W, F, K, A, Y or P), K83R, V89L, M96P, Q108L); wherein said residue numbers are Kabat residue numbers; and, optionally, a half-life extender (for example ALB11002) and/or a C-terminal extender (for example an alanine). For example, in one embodiment of the invention, the ISVD comprises the amino acid sequence:XVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTY YADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTVS S, where X is D or D: E); optionally comprising a half-life extender (for example ALB11002) and/or a C-terminal extender (for example an alanine). In one embodiment of the invention, the CTLA4 linker comprises an ISVD that includes the amino acid sequence selected from SEQ ID NOs: 93 to 109; optionally devoid of amino acids AAADYKDHDGDYKDHDIDYKDDDDKGAAHHHHHH thereof. In one embodiment of the invention, the CTLA4 linker comprises an ISVD that binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 60, wherein X is D or E; a peptide linker (for example, GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO:65)); an ISVD that binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 60, wherein X is D or E; a peptide linker; a half-life extender; and, optionally, a C-terminal extending alanine; or wherein the CTLA4 linker comprises an ISVD that binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 60, wherein X is D or E; a peptide linker; a half-life extender; and, optionally, a C-terminal extending alanine. In an embodiment of the invention, the CTLA4 ligand comprises the amino acid sequence: DVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRT YYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTV SSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGWQPGGSLR LSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTYYADSVKGRFTISRDNSKNTV YLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTVSSGGGGSGGGGSGGGGSGG GGSGGGGSGGGGSGGGGSEVQLVESGGGWQPGNSLRLSCAASGFTFSSFGMSWVRQ APGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTi GGSLSRSSQGTLVTVSSA (SEQ ID NO: 62); ouDVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRT YYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTV SSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGWQPGNSLR LSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTL YLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSA (SEQ ID NO: 64).
The present invention also provides a binder (e.g., an antibody) that cross-blocks a CTLA4 binder disclosed herein against binding to CTLA4.
[0019] The present invention also provides an injection container or device comprising any CTLA4 ligand shown herein (e.g. comprising the amino acid sequence shown in SEQ ID NO: 62 or 64) optionally in association with a therapeutic agent additional.
The present invention also provides a polynucleotide (e.g. DNA) encoding any CTLA4 linker shown herein (e.g. comprising the amino acid sequence shown in SEQ ID NO: 62 or 64); for example, comprising the nucleotide sequence of SEQ ID NO: 61 or 63; or a vector comprising such a polynucleotide; or a host cell comprising such a polynucleotide or vector.
[0021] The present invention also provides a method for making the CTLA4 linker shown herein (e.g. comprising the amino acid sequence shown in SEQ ID NO: 62 or 64) comprising introducing a polynucleotide encoding the CTLA4 linker into a host cell (e.g., a CHO cell or Pichia cell) and culturing the host cell in a medium under conditions favorable for expressing said CTLA4 linker from said polynucleotide and optionally purifying the CTLA4 linker from said host cell and/or said medium, as well as any CTLA4 ligand produced by such method.
[0022] The present invention also provides a method of preventing CTLA4 from binding to CD80 or CD86 (for example, on the body of an individual) comprising contacting said CTLA4 with the CTLA4 ligand (for example comprising the sequence of amino acids shown in SEQ ID NO: 62 or 64) optionally in association with an additional therapeutic agent; as well as a method of enhancing an immune response in the body of an individual (e.g. a human) comprising administering an effective amount of the CTLA4 ligand (e.g. comprising the amino acid sequence shown in SEQ ID NO: 62 or 64) to the individual optionally in association with an additional therapeutic agent (e.g., pembrolizumab). Furthermore, the present invention provides a method of treating or preventing cancer or an infectious disease in the body of a subject comprising administering an effective amount of CTLA4 ligand (e.g. comprising the amino acid sequence shown in SEQ ID NO: 62 or 64 ) optionally in association with an additional therapeutic agent (eg, pembrolizumab) to the subject. In one embodiment of the invention, the cancer is metastatic cancer, a solid tumor, a hematologic cancer, leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, breast cancer squamous cell, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid kidney tumor, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, acoustic neuroma, a primitive neuroectodermal tumor , medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelofibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer or liver cancer, breast cancer or gastric cancer; or where the infectious disease is a bacterial infection, a viral infection, or a fungal infection. In one embodiment of the invention, the subject is administered an additional therapeutic agent (eg, pembrolizumab) or a therapeutic procedure in association with the CTLA4 ligand. Description of figures
[0023] Figure 1. A table listing some of the amino acid positions that will be specifically mentioned in this document and their numbering according to some alternative numbering systems (such as Aho and IMGT)
[0024] Figure 2. CTLA4 ligand sequences.
[0025] Figure 3 (A-B). Alignment of the 11F1 sequence with that of SEQ ID NOs: 8 to 43.
[0026] Figure 4. Predominant N-linked glycans for monoclonal antibodies produced in Chinese hamster ovary cells (CHO N-linked glycans) and in modified yeast cells (modified yeast N-linked glycans): squares: N- acetyl glucosamine (GlcNac); circles: mannose (Man); diamonds: galactose (Gal); triangles: fucose (Fuc).
[0027] Figure 5 (A-B). bFACS Analysis of Nanobody F023700912, F023700925 or Control Nanobody (IRR00051; anti-HER2/ERBB2 (bivalent anti-HER2 with 35GS connected to albumin ligand)) that binds to (A) Jurkat and (B) CHO-K1 cells that express hCTLA4.
[0028] Figure 6 (A-B). Competition between Nanobody F023700912 or ipilimumab and (A) CD80 or (B) CD86 for binding to human CTLA4 expressed in CHO-K1 cells.
[0029] Figure 7 (A-H). Specificity assessment of Nanobody F023700912, F023700925 or Control Nanobody (IRR00051) for binding to BTLA, CD8, PD1, CTLA4, LAG3, CD28 or control cells. Nanobody binding was determined for (A) negative control L cells, (B) negative control CHO-K1 cells, (C) huCD28+ L cells, (D) huCD8alpha+ L cells, (E) huLag-3+ CHO cells -K1, (F) huBTLA+ CHO-K1 cells, (G) huCTLA-4+ CHO-K cells and (H) huPD-1 + CHO-K1 cells.
[0030] Figure 8 (A-B). Competition between F023700906, F023701051, F02371054 or F023701061 Nanobody and (A) human CD80 or (B) human CD86 for binding to human CTLA-4 expressed in CHO-K1 cells.
[0031] Figure 9 (A-J). Effect of Nanobody on panc 08.13 tumors in humanized mice. (A) mean ±SEM tumor volumes and (B) individual tumor volumes at day 37 in mice treated with isotype control, ipilimumab (N297A), ipilimumab, pembrolizumab, ipilimumab + pembrolizumab, F023700912 at a dosage of 5 mpk (CTLA4 Nab -5), F023700912 at a dosage of 15 mpk (CTLA4 Nab-15), or pembrolizumab + CTLA4 Nab-15; and tumor volumes in individual mice during the course of the experiment in mice treated with (C) antibody isotype control, (D) ipilimumab (N297A), (E) ipilimumab, (F) pembrolizumab, (G) ipilimumab + pembrolizumab, ( H) CTLA4 Nab-5, (I) CTLA4 Nab-15 or (J) CTLA4 Nab-15+ pembrolizumab.
[0032] Figure 10 (A-B). Serum preAb reactivity to F023700912 and F023700925 and a T013700112 trivalent control Nanobody (devoid of mutations to reduce pre-existing antibody binding) by (A) healthy human subject sera and (B) cancer patient sera.
[0033] Figure 11. CTLA4 Ligand Constructs.
[0034] Figure 12. CTLA4 ligand sequences.
[0035] Figure 13. Heat map of deuterium identification difference of human CTLA4 binding by CTLA4 ligand F023700912. Detailed description of the invention
The present invention provides ISVDs that comprise mutations that block the reactivity of pre-existing antibodies (pre-antibodies) to neo-epitopes within the ISVDs. Neoepitopes are epitopes within a protein that are described when the protein is mutated (eg, truncated) or its folding is altered. Pre-existing antibodies are antibodies that exist in a patient's body prior to receiving an ISVD. The ISVDs of the present invention are based, in part, on llama antibodies whose C-terminal constant domains have been removed; thereby exposing neo-epitopes at the C-terminus of VHH resulting in pre-antibody binding. It was found that the combination of mutations of residues 11 and 89 (eg, L11V and I89L or V89L) led to a surprising lack of preantibody binding. Mutations at residue 112 were also shown to considerably reduce preantibody binding. Buyse & Boutton (WO2015/173325) have included data showing that the combination of an L11V and V89L mutation provided a considerable improvement in reducing preantibody binding compared to either an L11V mutation alone or a V89L mutation alone. For example, Buyse & Boutton's Table H on page 97 showed comparative data for an ISVD with a V89L mutation alone (with or without C-terminal extension) and the same ISVD with a V89L mutation in combination with an L11V mutation (again , with or without a C-terminal extension). Furthermore, although generated in two separate experiments, the data shown in Table H for the L11V/V89L combination compared to the data provided in Table B for an L11V mutation alone (in the same ISVD) showed that pre-binding reduction -antibody that is obtained by the L11V/V89L combination was greater than for the L11V mutation alone. Since the llama antibody framework structure is known to be very highly conserved, the effect of mutations at positions 11 and 89 is more likely to exist for any ISVD. In fact, the effect was demonstrated, in Figure 10, with the present ligands, F023700912 and F023700925, which were shown to exhibit very low levels of pre-antibody binding.
In the present application, amino acid residues/positions in an immunoglobulin heavy chain variable domain will be indicated with numbering according to Kabat. For convenience, Figure 1 provides a Table listing some of the amino acid positions that will be specifically mentioned in this document and their numbering according to some alternative numbering systems (such as Aho and IMGT. Note: except where explicitly stated in otherwise, for the present description and claims, the Kabat numbering is decisive; other numbering systems are given for reference only).
[0038] Regarding CDRs, as is well known in the art, there are multiple conventions to define and describe the CDRs of a VH or VHH fragment, such as the Kabat definition (which is based on sequence variability and is the most commonly used used) and the Chotia definition (which is based on the location of the structural loop regions). Reference is made, for example, to the website www.bioinf.org.uk/abs/. For the purposes of this specification and claims, although CDRs according to Kabat may also be mentioned, CDRs are most preferably defined based on the definition of Abm (which is based on Oxford's AbM antibody modeling software Molecular), as this is considered an ideal compromise between the definitions of Kabat and Chotia. Reference is again made to the website www.bioinf.org.uk/abs/. See Sequences of Proteins of Immunological Interest, Kabat, et al.; National Institutes of Health, Bethesda, Md.; 5th edition; NIH publication number 91-3242 (1991); Kabat (1978) Adv. Prot. Chem. 32:1-75; Kabat, et al., (1977) J. Biol. Chem. 252:66096616; Chothia, et al., (1987) J Mol. Biol. 196:901-917 or Chothia, et al., (1989) Nature 342:878-883; Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Elvin A. Kabat, Tai Te Wu, Carl Foeller, Harold M. Perry, Kay S. Gottesman (1991) Sequences of Proteins of Immunological Interest; Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). In one embodiment of the invention, the determination of CDR is according to Kabat, for example, where FR1 of a VHH comprises the amino acid residues at positions 1 to 30, CDR1 of a VHH comprises the amino acid residues at positions 31 to 35 , FR2 of a VHH comprises the amino acids at positions 36 to 49, CDR2 of a VHH comprises the amino acid residues at positions 50 to 65, FR3 of a VHH comprises the amino acid residues at positions 66 to 94, CDR3 of a VHH comprises the amino acid residues at positions 95 to 102 and FR4 of a VHH comprises amino acid residues at positions 103 to 113.
[0039] In one embodiment of the invention, the CDRs are determined according to Kontermann and Diibel (Eds., Antibody Engineering, vol 2, Springer Verlag Heidelberg Berlin, Martin, chapter 3, pages 33 to 51, 2010).
The term "single immunoglobulin variable domain" (also referred to as "ISV" or ISVD") is generally used to refer to immunoglobulin variable domains (which may be heavy chain or light chain domains, including VH domains , VHH or VL) which can form a functional antigen-binding site without interaction with another variable domain (eg without a VH/VL interaction as required between the VH and VL domains of conventional 4-chain monoclonal antibody) Examples of ISVDs will be apparent to those skilled in the art and, for example, include Nanobodies (including a VHH, a humanized VHH and/or camelized VHs like camelized human VHs), IgNAR, domains, antibodies (single domain) (as dAbs ™) which are VH domains or which are derived from a VH domain and antibodies (single domain) (such as dAbs™) which are VL domains or which are derived from a VL domain ISVDs are based on and/or are derived from variable domains heavy chain (like domain (VH or VHH) are generally preferred. Most preferably, an ISVD will be a Nanobody. For example, F023700906 is an ISVD.
[0041] The term "Nanobody" is generally as defined in WO 2008/020079 or WO 2009/138519, and thus, in a specific aspect, generally denotes a VHH, a humanized VHH or a camelized VH (such as a camelized human VH) or in general a sequence-optimized VHH (such as optimized for chemical stability and/or solubility, maximum overlap with known human framework regions, and maximum expression). It is noted that the terms Nanobody or Nanobodies are registered trademarks of Ablynx N.V. and as such may also be referred to as Nanobody® and/or Nanobodies®).
A multispecific linker is a molecule comprising a first CTLA4 binding moiety (eg an ISVD or a Nanobody) and one or more (eg 1, 2, 3, 4, 5) additional binding moieties (for example, ISVDs or Nanobodies) that bind to an epitope other than that of the first CTLA4 binding moiety (for example, an epitope other than CTLA4, or to CD27, LAG3, PD1 or BTLA).
[0043] A binding moiety, binding domain or binding unit is a molecule, such as an ISVD or Nanobody (for example, any one of SEQ ID NOs: 8 to 43 or 60), that binds to an antigen such as CTLA4 . The binding moiety, binding domain or binding moiety can be part of a larger molecule such as a multispecific or multivalent linker that includes more than one moiety, domain or moiety that can comprise another functional element, such as an extender half-life (HLE), targeting unit, and/or a small molecule such as polyethylene glycol (PEG).
[0044] A monovalent CTLA4 ligand (eg, ISVD as a Nanobody) is a molecule comprising a single antigen-binding domain. A bivalent CTLA4 ligand (eg, ISVD as a Nanobody) comprises two antigen-binding domains. A multivalent CTLA4 binder comprises more than one antigen-binding domain (for example, 1, 2, 3, 4, 5, 6 or 7).
[0045] A monospecific CTLA4 ligand (eg, ISVD as a Nanobody) binds to a single antigen (CTLA4); a bispecific CTLA4 ligand binds to two different antigens and a multispecific CTLA4 ligand binds to more than one antigen.
[0046] A biparatopic CTLA4 ligand (eg, ISVD as a Nanobody) is monospecific, but binds to two different epitopes of the same antigen. A multiparatopic CTLA4 ligand binds to the same antigen but to more than one epitope on the antigen.
[0047] The term "half-life", as used herein in relation to a CTLA4 ligand (eg ISVD as a Nanobody) or other molecule, can generally be defined as described in paragraph o) on page 57 of WO 2008 /020079 and as mentioned therein, refers to the time taken for the serum concentration of the amino acid sequence, CTLA4 ligand, compound or polypeptide to be reduced by 50% in vivo, for example, due to degradation of the sequence or compound and/ or depuration or sequestration of the sequence or composite by natural mechanisms. The in vivo half-life of an amino acid sequence, CTLA4 ligand, compound or polypeptide of the invention can be determined in any individually known manner, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art and may generally be, for example, as described in paragraph o) on page 57 of WO 2008/020079. As mentioned in paragraph o) on page 57 of WO 2008/020079, half-life can be expressed using parameters such as t1/2- alpha, t1/2-beta and area under the curve (AUC). In this regard, it should be noted that the term "half-life", as used herein, in particular refers to the t1/2-beta or terminal half-life (in which the t1/2-alpha and/or the AUC, or both, can be kept out of consideration). Reference is made, for example, to the Experimental Part below, as well as to standard manuals such as Kenneth, A et al: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and Peters et al, Pharmacokinete analysis: A Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D Perron, published by Marcel Dekker, 2nd edition rev. (1982). Similarly, the terms "increased half-life" or "increased half-life" are also as defined in paragraph o) on page 57 of WO 2008/020079 and in particular refer to an increase in t1/2 - beta, with or without an increase in t1/2-alpha and/or AUC, or both.
[0048] When a term is not specifically defined herein, it has its common meaning in the art, which will be evident to the person skilled in the art. Reference is made, for example, to standard manuals such as Sambrook et al, "Molecular Cloning: A Laboratory Manual" (2nd edition), Volumes 1 to 3, Cold Spring Harbor Laboratory Press (1989); F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987); Lewin, "Genes II", John Wiley & Sons, New York, N.Y., (1985); Old et al, "Principles of Gene Manipulation: An Introduction to Genetic Engineering", 25th edition, University of California Press, Berkeley, CA (1981); Roitt et al, "Immunology" (6th edition), Mosby/Elsevier, Edinburgh (2001); Roitt et al, Roitt's Essential Immunology, 10th edition Blackwell Publishing, UK (2001); and Janeway et al, "Immunobiology" (6th edition), Garland Science Publishing/Churchill Livingstone, New York (2005), as well as the general fundamentals of the technique cited herein.
[0049] For a general description of multivalent and multispecific polypeptides containing one or more Nanobodies and their preparation, reference is also made to Conrath et al, J. Biol. Chem., Vol. 276, 10. 7,346 to 7,350, 2001; Muyldermans, Reviews in Molecular Biotechnology 74 (2001), 277 to 302; as well as, for example, WO 1996/34103, WO 1999/23221, WO 2004/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or WO 2009/068627.
CTLA4 ligands (eg, ISVD as a Nanobody), "isolated" polypeptides, polynucleotides, and vectors are at least partially free of other biological molecules from the cells or cell culture from which they were produced. Such biological molecules include nucleic acids, proteins, lipids, carbohydrates or other material such as cell debris and growth medium. An "isolated" CTLA4 ligand may additionally be at least partially free of expression system components such as biological molecules of a host cell or growth medium thereof. In general, the term "isolated" is not intended to refer to a complete absence of such biological molecules or an absence of water, buffers or salts or components of a pharmaceutical formulation that includes the antibodies or fragments.
[0051] The phrase "control sequences" refers to polynucleotides necessary for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to use promoters, polyadenylation signals and enhancers.
[0052] A nucleic acid or polynucleotide is "operably linked" when it is placed into a functional relationship with another polynucleotide. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked if it is positioned to facilitate translation. In general, but not always, "operably linked" means that the DNA sequences that are linked are contiguous and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by linking to convenient restriction sites. If such sites do not exist, synthetic oligonucleotide linkers or adapters are used in accordance with conventional practice.
[0053] "Human serum albumin binders" or "HSA binders" of the present invention are any of the molecules described herein that bind to HSA (e.g., an ISVD such as a Nanobody), as well as any antibody or binding fragments to the antigen thereof that binds to HSA and includes any of the HSA binding moieties described herein. An individual HSA linker may be mentioned as having an HSA binding moiety if it is part of a larger molecule, for example a multivalent molecule like F023700912 or F023700914.
In general, the basic antibody structural unit comprises a tetramer. Each tetramer includes two identical pairs of polypeptide chains, each pair having a "light" chain (about 25 kDa) and a "heavy" chain (about 50 to 70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function. Typically, human light chains are classified as kappa and lambda light chains. Additionally, human heavy chains are typically classified as mu, delta, gamma, alpha or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA and IgE, respectively. Within the heavy and light chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 amino acids more. See, in general, Fundamental Immunology Chapter 7 (Paul, W., ed., 2nd edition, Raven Press, N.Y. (1989).
[0055] Examples of antigen binding fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, and single-chain Fv molecules.
[0056] The following properties are associated with the indicated mutations in the CTLA4 ligand 11F01:E1D: Prevent the formation of pyroglutamic acid in the first amino acid of the E1L11V construct: Decrease binding of pre-antibody A14P: HumanizationQ45R: Mutated to increase stabilityA74S: HumanizationK83R: Humanization I89L: Decrease pre-antibody binding M96P, Q or R: Prevent oxidation of M96Q108L: Humanization
[0057] In one embodiment of the invention, CTLA4 is human CTLA4. In one embodiment of the invention, human CTLA4 comprises the amino acid sequence: MACLGFQRHK AQLNLATRTW PCTLLFFLLF IPVFCKAMHV AQPAWLASSRGIASFVCEY ASPGKATEVR VTVLRQADSQ VTEVCAATYM MGNELTFLDD SICTGTSSGN QVNLTIQGLR AMDTGLYICK VELMYPPPYY LGIGNGTQIY VIDPEPCPDS DFLLWILAAV SSGLFFYSFL LTAVSLSKML KKRSPLTTGV YVKMPPTEPE CEKQFQPYFI PIN (SEQ ID NO: 111) of CTLA4 Ligands
The present invention aims to provide improved CTLA4 binders, in particular, improved CTLA4 ISVDs, and more particularly, improved CTLA4 Nanobodies. CTLA4 binders of the present invention include polypeptides that are polypeptide variants comprising the amino acid sequence of SEQ ID NO: 1 that is mutated at position such as 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112.
A CTLA4 or ISVD ligand of CTLA4 or CTLA4 Nanobody refers to a ligand, ISVD or Nanobody, respectively, that binds to CTLA4.
The improved CTLA4 binders provided by the invention are also referred to herein as the "CTLA4 binders of the invention" or "CTLA4 binders". These terms encompass any molecule comprising a molecule that is shown herein that binds to CTLA4. For example, the terms include an ISVD comprising an amino acid sequence shown in a member selected from the group consisting of SEQ ID NOs: 8 to 43 and 60, as well as any polypeptide, Nanobody, ISVD, fusion protein, conventional antibody or antigen-binding fragment thereof, which includes an amino acid sequence shown in a member selected from the group consisting of SEQ ID NOs: 8 to 43 and 60; or any bispecific molecule (eg, an ISVD) that comprises an amino acid sequence displayed in a member selected from the group consisting of SEQ ID NOs: 8 to 43 and 60, binds to CTLA4 and also binds to another antigen or another epitope such as CD27, LAG3, PD1 or BTLA. A CTLA4 binder of the present invention is F023700912 or F023700914.
[0061] The scope of the present invention includes any CTLA4 ligand comprising the arrangement of binding moieties shown in Figure 11, optionally devoid of FLAG3 and/or HIS6 tags; as well as any of the amino acid sequences shown in Figure 12.
[0062] WO 2008/071447 describes Nanobodies that can bind CTLA4 and uses thereof. SEQ ID NO: 1306 of WO 2008/071447 described a CTLA4-specific Nanobody called 11F01, whose sequence is given herein as SEQ ID NO: 1. That sequence (also referred to herein as "Reference A") and its CDRs are also given in the Table A-1 below.
[0063] As further described herein, CTLA4 binders of the invention that are, in one embodiment of the invention, in multivalent and/or multispecific CTLA4 binders of the present invention (e.g., F023700914), preferably have the same combination of CDRs (i.e., CDR1, CDR2 and CDR3) as present in 11F01 or in a linker comprising the sequence of 11F01 (SEQ ID NO: 1). See Table A-1.
The present invention also includes CTLA4 linkers that are 11F01 variants that comprise an amino acid sequence as shown below in Table A-2. The scope of the present invention includes CTLA4 binders which include CDR1, CDR2 and CDR3 of said variants shown below in Table A-2.
[0065] Furthermore, the multispecific and/or multivalent linkers of the present invention (e.g. F023700914) comprising a CTLA4 binding moiety which includes CDR1, CDR2 and CDR3 or the amino acid sequence of 11F01 or one of its variants shown below in Table A-2.Table A-1. CTLA4 11F1 nanobody (11F01).

*CDRs underlined and/or in bold
Residue 1 of SEQ ID NO: 60 can be D or E. If residue 1 is D, the CTLA4 linker can be designated as 1D and if residue 1 is E, the CTLA4 linker can be designated as 1E.
[0067] In one embodiment of the invention, a CTLA4 linker of the present invention comprises a mutation N73X, where X is any amino acid other than N, e.g., S, V, G, R, Q, M, H, T, D, E, W, F, K, A, Y or P (or any amino acid other than N).
[0068] The present invention includes CTLA4 binders comprising one, two or three CDRs of a CTLA4 binder, each comprising 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 substitutions of amino acids, for example, conservative substitutions and/or comprises 100, 99, 98, 97, 96 or 95% sequence identity to the CDRs that are in the CTLA4 linker sequences shown in Table A-1 or A-2 (for example, 11F01 (E1D, L11V, A14P, Q45R, A74S, K83R, V89L, M96P, Q108L) or 11F01), or are shown in SEQ ID NOs: 2 to 7, wherein a CTLA4 linker having such CDRs retains the ability to bind CTLA4.
[0069] The Kabat residue numbers for certain residues of CTLA4 ligands (e.g., ISVD as a Nanobody) that is based on the Reference A, which are presented here are shown in the sequence below: E1VQLVESGGGL11V12Q13A14GGSLRLSCAASG26G27T28F29S30FYGMGW36F37R38Q39AP GKEQ45E46F47V48A49DIRTSAGRTYYADSVKGR66F67T68l69S70RDN73A74KNTVYLQMN82a S82bL82cK83P84EDT87A88V89Y90Y91CAAEM96SGISGWDYW103G104Q105G106TQ108V109T110 V111S112S113 (SEQ ID NO: 1)
[0070] residue numbers Kabat for certain binding residues of CTLA4 11F01 (E1D, L11V, A14P, Q45R, A74S, K83R, V89L, M96P, Q108L) that are presented here are shown in the sequence below: D1VQLVESGGGV11VQP14GGSLRLSCAASGGTFSFYGMGWFRQAPGKER45EFVADIRTSAGRTYYADSVKGRFTISRDNS74KNTVYLQMNSLR83PEDT AL89YYCAAEP96SGISGWDYWGQGTL108VTVSS (SEQ ID NO: 60)
The present invention includes any CTLA4 linker comprising the amino acid sequence of SEQ ID NO: 60 or an amino acid sequence comprising 80% or more (e.g. 85%, 90%, 95%, 96%, 97% , 98% or 99%) amino acid sequence identity, wherein the CTLA4 linker retains the ability to bind CTLA4.
[0072] The present invention includes embodiments wherein the CDR3 methionine of a CTLA4 linker, at position Kabat 96, is replaced with any amino acid such as proline (but not with Cys, Asp or Asn), for example, by any of the following amino acids: Leu, Ile, Val, Ala, Gly, Tyr, Trp, Phe, Glu, Gln, Ser, Thr, His, Arg, Lys or Pro.
Some preferred, but not limiting, CTLA4 binders (e.g., ISVD as a Nanobody) of the invention are SEQ ID NO: 60 or are listed in Figure 2 as SEQ ID NOs: 8 to 43. Figure 3 shows an alignment of those sequences with Reference A (SEQ ID NO: 1). Among such CTLA4 linkers, the linkers of SEQ ID NOs: 26 to 43 are examples of CTLA4 linkers of the invention having a C-terminal alanine extension, i.e., an alanine residue at the C-terminal end of the ISVD sequence ( also sometimes referred to as "position 114") compared to the usual C-terminal sequence VTVSS (SEQ ID NO: 57, as presented in Reference A). As described in WO 2012/175741 (but also, for example, in WO 2013/024059 and PCT/EP2015/060643 (WO2015/173325)), such a C-terminal alanine extension can prevent the binding of so-called "pre-existing antibodies " (assumed to be IgGs) to a putative epitope that is situated in the C-terminal region of the ISV. This epitope is presumed to include, among other residues, the surface exposed amino acid residues of the C-terminal sequence VTVSS (SEQ ID NO: 57), as well as the amino acid residue at position 14 (and the amino acid residues alongside /near the same in the amino acid sequence, such as positions 11, 13 and 15) and may also comprise the amino acid residue at position 83 (and the amino acid residues beside/near it in the amino acid sequence, such as positions 82, 82a , 82b and 84) and/or the amino acid residue at position 108 (and the amino acid residues next to/near it in the amino acid sequence, as position 107).
[0074] However, although the presence of such a C-terminal alanine (or an extension of the C-terminal in general) can greatly reduce (and in many cases even completely prevent) the binding of "pre-existing antibodies" that can be found in the sera of a range of individuals (both healthy individuals and patients), it has been found that sera from some individuals (such as sera from patients with some immune diseases such as SLE) may contain pre-existing antibodies that can bind to the region. C-terminus of an ISV (when such region is exposed), even when the ISV contains such a C-terminal alanine (or more generally, such an extension of the C-terminus). Reference is again made to co-pending unprepublished PCT application PCT/EP2015/060643 (WO2015/173325) by Ablynx N.V. filed May 13, 2015 and entitled "Improved immunoglobulin variable domains".
Accordingly, a specific object of the invention is to provide CTLA4 ligands (e.g. ISVD as a Nanobody) which are improved variants of the CTLA4 Nanobody mentioned herein as "Reference A" and which have reduced binding by so-called "pre-antibodies existing", and, in particular, of the type described in PCT/EP2015/060643 (WO2015/173325) (i.e. those pre-existing antibodies that can bind to an exposed C-terminal region of an ISV even in the presence of an C-terminal extension).
The invention provides CTLA4 linkers comprising amino acid sequences that are variants of the sequence of SEQ ID NO: 1 that comprise one or more of the following mutations compared to the sequence of SEQ ID NO: 1:-1D or 1E; - 11V; - 14P; - 45R; - 74S; - 83R; - 89L or 89T; - 96P; or - 108L; for example, wherein the CTLA4 ligand comprises one or more of the sets of mutations below: - 89L in combination with 11V; 14P; 45R; 74S; 83R; 86P; 108L and 1E or 1D;- 89L in combination with 11V;- 89L in combination with 110K or 110Q;- 89L in combination with 112K or 112Q;- 89L in combination with 11V; 14P; 45R; 74S; 83R; 86P;108L, 110K or 110Q and 1E or 1D;- 89L in combination with 11V; 14P; 45R; 74S; 83R; 86P;108L, 112K or 112Q and 1E or 1D; - 89L in combination with 11V and 110K or 110Q; - 89L in combination with 11V and 112K or 112Q; - 11V in combination with 110K or 110Q; and/or-11V in combination with 112K or 112Q.
[0077] In particular, in an embodiment of the invention, the CTLA4 linkers (for example, ISVD as a Nanobody) comprise:- the amino acid at position 1 is preferably E or D;- the amino acid at position 11 is from preferably L or V; - the amino acid at position 14 is preferably A or P; - the amino acid at position 45 is preferably Q or R; - the amino acid at position 74 is preferably A or S ; - the amino acid at position 83 is preferably K or R; - the amino acid at position 89 is preferably T, V or L; - the amino acid at position 96 is preferably M or P; - the amino acid at position 108 is preferably Q or L; the amino acid residue at position 110 is preferably suitably chosen from T, K or Q; e- the amino acid residue at position 112 is preferably suitably chosen from S, K or Q; such that, for example, one or more of the following is true: (i) position 89 is T;( ii) position 89 is L; (iii) position 1 is D or E, position 11 is V, position 14 is P, position 45 is R, position 74 is S, position 83 is R, position 89 is L, position 96 is P, and position 108 is L; (iv) position 89 is L and position 11 is V; (v) position 89 is L and position 110 is K or Q; (vi) position 89 is L and position 112 is K or Q ;(vii) position 1 is D or E, position 11 is V, position 14 is P, position 45 is R, position 74 is S, position 83 is R, position 89 is L, position 96 is P, position 108 is L ; and position 110 is K or Q; (viii) position 1 is D or E, position 11 is V, position 14 is P, position 45 is R, position 74 is S, position 83 is R, position 89 is L, position 96 is P, position 108 is L; and position 112 is K or Q; (ix) position 89 is L and position 11 is V and position 110 is K or Q; (x) position 89 is L and position 11 is V and position 112 is K or Q;(xi ) position 11 is V and position 110 is K or Q; or (xii) position 11 is V and position 112 is K or Q.
In particular embodiments, CTLA4 linkers (e.g., an ISVD such as a Nanobody) of the invention comprise amino acid sequences that are variants of SEQ ID NO: 1, where position 89 is T or where position 1 is D, position 11 is V, position 14 is P, position 45 is R, position 74 is S, position 83 is R, position 89 is L, position 96 is P and position 108 is L or where position 11 is V and position 89 is L (optionally in suitable combination with a 110K or 110Q mutation and/or a 112K or 112Q mutation, and in particular in combination with a 110K or 110Q mutation) are particularly preferred. Even more preferred are amino acid sequences where position 11 is V and position 89 is L, optionally with a 110K or 110Q mutation.
As mentioned, CTLA4 ligands (eg, ISVD as a Nanobody) described herein can bind (and, in particular, can specifically bind) CTLA4. In one embodiment of the invention, CTLA4 ligands can bind CTLA4 and thereby prevent CD80 and CD86 on antigen-presenting cells from binding to CTLA-4 on T cells. of CTLA-4 prolongs T cell activation, restores T cell proliferation, and thus amplifies T cell-mediated immunity, which theoretically enhances the patient's ability to mount an anti-tumor immune response.
[0080] In one embodiment of the invention, a CTLA4 ligand of the present invention has one or more of the following properties: • Binds to CTLA4 (eg, human and/or cynomolgus monkey CTLA4 (CTLA4-Fc fusion protein) ), for example, with a KD of about 1 nM (eg 1.2 nM);• Binds to CTLA4 on the surface of a cell, for example, a CHO cell expressing CTLA4;• Blocks the binding of CD80 or CD86 to CTLA4 (eg CTLA4 expressed in CHO cells);• Does not bind to BTLA, CD8, PD1, LAG3 and/or CD28;• Does not bind in vitro and/or in vivo to human, monkey serum albumin rhesus and mouse (when fused to one or more ALB11002 ligands);• Inhibits tumor growth (eg, from pancreatic tumors, eg, human pancreatic tumors in a mouse harboring human immune cells).
[0081] Table B lists some possible non-limiting combinations of amino acid residues that may be present at positions 11, 89, 110 and 112 (of SEQ ID NO: 1) in CTLA4 linkers (e.g., ISVD as a Nanobody) of invention.Table B: Possible combinations of mutations at amino acid positions 11, 89, 110 and 112 in CTLA4 linker variants of SEQ ID NO:1.


The CTLA4 binders (e.g. ISVD as a Nanobody) provided by the invention are further as described in the description, examples and figures herein, i.e. they have CDRs which are as described herein and have a full degree of identity of sequence (as defined herein) with the sequence of SEQ ID NO: 1 which is as described herein and/or may have a limited number of "amino acid differences" (as described herein) with (one of) such reference sequences.
The CTLA4 binders (e.g. ISVD as a Nanobody) of the invention preferably comprise the following CDRs (according to the Kabat convention):- a CDR1 (according to Kabat) comprising the sequence of amino acids FYGMG (SEQ ID NO: 2); and - a CDR2 (according to Kabat) comprising the amino acid sequence DIRTSAGRTYYADSVKG (SEQ ID NO: 3); and - a CDR3 (according to Kabat) comprising the amino acid sequence EPSGISGWDY (SEQ ID NO: 4); optionally, where CDR1, CDR2 and/or CDR3 comprises 1, 2, 3, 4, 5, 5, 6, 7, 8, 9 or 10 substitutions, for example, conservative substitutions.
[0084] Alternatively, when the CDRs are given in accordance with the Abm convention, the CTLA4 binders (eg ISVD as a Nanobody) of the invention preferably comprise the following CDRs:- a CDR1 (according to Abm ) which is the amino acid sequence GGTFSFYGMG (SEQ ID NO: 5); e- a CDR2 (according to Abm) which is the amino acid sequence DIRTSAGRTY (SEQ ID NO: 6); e- a CDR3 (according to Abm) which is the amino acid sequence EPSGISGWDY (SEQ ID NO:7 which is equal to SEQ ID NO:4); optionally, where CDR1, CDR2 and/or CDR3 comprises 1, 2, 3, 4, 5, 5, 6, 7, 8, 9 or 10 substitutions, for example, conservative substitutions.
[0085] A CTLA4 ligand (e.g., ISVD as a Nanobody) of the invention, in one embodiment of the invention, has such CDRs and mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112, as discussed herein, and optionally:- a degree of sequence identity with the amino acid sequence of SEQ ID NO: 1 of at least 85%, preferably at least 90%, more preferably at least 95 % (where the CDRs, any extension of the C-terminus that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, where the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective sequences. reference sequences (eg, expected threshold: 10; word length: 3; correlations maximum s in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; conditional compositional scoring matrix adjustment); and/or- no more than 7, such as no more than 5, preferably no more than 3, such as only 3, 2 or 1 "amino acid difference" with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or in the CDRs, but are preferably present only in the structures and not in the CDRs; not taking into account any C-terminal extension that may be present and not taking into account count mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved).
[0086] The following references refer to BLAST algorithms often used for sequence analysis: BLAST ALGORITHM: Altschul et al. (2005) FEBS J. 272(20): 5,101 to 5109; Altschul, S.F., et al. (1990) J. Mol. Biol. 215:403 to 410; Gish, W., et al, (1993) Nature Genet. 3:266 to 272; Madden, T.L., et al, (1996) Meth. Enzymol. 266: 131 to 141; Altschul, S.F., et al, (1997) Nucleic Acids Res. 25:3,389 to 3,402; Zhang, J., et al, (1997) Genome Res. 7:649 to 656; Wootton, J.C., et al, (1993) Comput. Chem. 17: 149 to 163; Hancock, J.M. et al, (1994) Comput. Appl. Biosci. 10:67 to 70; ALIGNMENT SCORING SYSTEMS: Dayhoff, M.O., et al, "A model of evolutionary change in proteins." in Atlas of Protein Sequence and Structure, (1978) vol. 5, supp. 3. M.O. Dayhoff (ed.), pages 345 to 352, Natl. Biomed. Res. Found., Washington, DC; Schwartz, R.M., et al, "Matrices for detecting distant relationships." in Atlas of Protein Sequence and Structure, (1978) vol. 5, supp. 3. MO Dayhoff (ed.), pages 353 to 358, Natl. Biomed. Res. Found., Washington, DC; Altschul, SF, (1991) J. Mol. Biol. 219:555 to 565; States, DJ , et al, (1991) Methods 3:66 to 70; Henikoff, S., et al, (1992) Proc. Natl. Acad. Sci. USA 89: 10,915 to 10,919; Altschul, SF, et al, (1993) J. Mol. Evol. 36:290 to 300; ALIGNMENT STATISTICS: Karlin, S., et al, (1990) Proc. Natl. Acad. Sci. USA 87:2.264 to 2268; Karlin, S., et al, (1993) Proc. Natl. Acad. Sci. USA 90:5,873 to 5,877; Dembo, A., et al. (1994) Ann. Prob. 22:2022 to 2,039; and Altschul, SF "Evaluating the statistical significance of multiple distinct local alignments." in Theoretical and Computational Methods in Genome Research (S. Suhai, ed.), (1997) pages 1-14, Plenum, New York.
In relation to the various aspects and preferred aspects of the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention provided by the invention, when it comes to the degree of sequence identity with respect to SEQ ID NO: 1 and/or of the number and type of "amino acid differences" that may be present in such a linker of the invention (i.e., compared to the sequence of SEQ ID NO: 1), it should be noted that when it is mentioned that:(i) an amino acid sequence of the invention has a degree of sequence identity with the sequence of SEQ ID NO: 1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, where Algorithm meters are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; word size: 3; maximum correlations within a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; conditional compositional scoring matrix adjustment); and/or when it is mentioned that: (ii) an amino acid sequence of the invention has no more than 7, preferably no more than 5, such as only 3, 2 or 1 "differences from amino acid" with the sequence of SEQ ID NO: 1 (again, not taking into account any C-terminal extension that may be present and not taking into account mutations at positions 1, 11, 14, 45, 74, 83 , 89, 96, 108, 110 and/or 112 required by the specific aspect involved), then this also includes sequences that have no amino acid differences with the sequence of SEQ ID NO: 1 other than mutations at positions 1, 11, 14 , 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved) and any C-terminal extension that may be present.
[0088] Thus, in a specific aspect of the invention, the CTLA4 linkers (e.g., ISVD as a Nanobody) of the invention comprise the amino acid sequence of SEQ ID NO: 1, but wherein at least 1 amino acid mutation in position 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 is substituted (e.g., conservatively substituted) and can have 100% sequence identity with SEQ ID NO: 1 (including the CDRs, but not taking into account the mutation (or mutations) or combination of mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 disclosed herein document and/or any C-terminal extension that may be present) and/or may have no amino acid difference with SEQ ID NO: 1 (i.e., different from the mutation(s) or combination of mutations at positions 1 , 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 described herein and any C-terminal extension that may be present).
[0089] When any amino acid differences are present (ie, in addition to any C-terminal extension and mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 which are required by the specific aspect of the invention involved), such amino acid differences may be present in the CDRs and/or framework regions, but are preferably present only in the framework regions (as defined by the Abm convention, i.e. , not in the CDRs as defined according to the Abm convention), that is, so that the CTLA4 binders (eg ISVD as a Nanobody) of the invention have the same CDRs (defined according to the Abm convention) which are present in SEQ ID NO: 1 or 60.
[0090] Furthermore, when a CTLA4 linker (e.g. ISVD as a Nanobody) of the invention according to any aspect of the invention has one or more amino acid differences with the sequence of SEQ ID NO: 1 (in addition to mutations in the positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that are required by the specific aspect involved), then some specific but non-limiting examples of such amino acid mutations/differences which may be present (i.e. compared to the sequences of SEQ ID NO: 1) are, for example, E1D, P41A, P41L, P41S or P41T (and in particular P41A) and/or T87A (for example, E1D (optional), L11V, A14P, Q45R, A74S, K83R, V89L, M96P and Q108L). Other examples of mutations are (a suitable combination of) one or more suitable "humanization" substitutions such as Q108L; Reference is made, for example, to documents under WO 2009/138519 (or in the prior art cited in WO 2009/138519) and WO 2008/020079 (or in the prior art cited in WO 2008/020079) as well as the Tables A-3 to A-8 of WO 2008/020079 (which are lists showing possible humanization substitutions). Preferably, the CTLA4 binders of the invention contain at least one Q108L humanizing substitution.
[0091] Furthermore, when the CTLA4 ligands (e.g., ISVD as a Nanobody) of the invention are present in and/or from the N-terminal part of the CTLA4 ligand, where they are present then from preferably, they contain a D at position 1 (i.e. a mutation in E1D compared to Reference A). Some preferred, but non-limiting, examples of such N-terminal CTLA4 linkers are given as SEQ ID NOs: 24 and 25 and 60. Accordingly, in a further aspect, the invention relates to a polypeptide of the invention (which is as described herein). additionally herein) which has a CTLA4 linker of the invention (which is as further described herein) at its N-terminal end, wherein said CTLA4 linker of the invention has a D at position 1, and is, of preferably, chosen from the CTLA4 linkers of SEQ ID NOs: 24 and 25 and 60.
[0092] Similarly, when a CTLA4 linker (eg, ISVD as a Nanobody) of the invention is used in the monovalent format, it preferably has both an X(n) C-terminal extension as described herein. as a D at position 1. Some preferred but non-limiting examples of such monovalent CTLA4 linkers are given as SEQ ID NOs: 42 and 43. Accordingly, in a further aspect, the invention relates to a monovalent CTLA4 linker of invention (which is as further described herein) which has a D at position 1 and a C-terminal extension X(n) (which is preferably a single residue of Ala). In a specific aspect, said monovalent CTLA4 linker is chosen from SEQ ID NOs: 42 or 43. By way of preferred but non-limiting examples, SEQ ID NOs: 22 to 25 and 40 to 42 and 60 are examples of CTLA4 linkers (e.g., ISVD as a Nanobody) of the invention that have additional amino acid differences with SEQ ID NO: 1, i.e., A14P, Q45R, A74S, K83R and/or Q108L (in addition, as indicated in the preceding paragraphs , SEQ ID NOs: 24, 25, 42 and 43 also have a mutation in E1D). Thus, in a specific aspect, the invention relates to CTLA4 ligands of the invention (i.e., which have mutations at positions 11, 89, 110 and/or 112 as described herein and also being additionally as described herein. ) that have at least one suitable combination of an optional E1D mutation, A14P mutation, a Q45R mutation, an A74S mutation, a K83R mutation and a Q108L mutation, and preferably a suitable combination of Q108L with any of the others mutations A14P, Q45R, A74S and K83R, and preferably in combination with any two of these other mutations, more preferably with any three of these mutations (as with the combination of A14P, A74S and K83R or E1D, L11V, A14P, Q45R, A74S, K83R, V89L, M96P and Q108L), as with all such mutations (and again, when the CTLA4 linker is monovalent or is present at the N-terminal end of a CTLA4 linker of the invention, preferably, also a mutation in E1D).
[0093] CTLA4 linkers (eg ISVD as a Nanobody) of the invention, when they are used in a monovalent format and/or when a CTLA4 binding moiety is present in and/or forms the C-terminal end of the CTLA4 linker (or when they otherwise have an "exposed" C-terminal end on such a polypeptide, by which it generally means that the C-terminal end of the ISVD is not associated with or linked to a constant domain (such as a domain CHI); reference is made again to WO 2012/175741 and PCT/EP2015/060643 (WO 2015/173325)), preferably they also have a C-terminal extension of Formula (X)n, where n is 1 to 10 preferably 1 to 5 such as 1, 2, 3, 4 or 5 (and preferably 1 or 2 such as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen from naturally occurring amino acid residues (although, in a preferred aspect, it does not comprise any cysteine residue), and preferably , independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
[0094] According to some preferred but non-limiting examples of such C-terminal extensions X(n), X and n can be as follows: (a) n = 1 and X = Ala;(b) n = 2 and each X = Ala;(c) n = 3 and each X = Ala; (d) n = 2 and at least one X = Ala (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile); (e) n = 3 and at least one X = Ala (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile); (f) n = 3 and at least two X = Ala (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile);(g) n = 1 and X = Gly;(h) n = 2 and each X = Gly; (i) n = 3 and each X = Gly;(j) n = 2 and at least one X = Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile); (k) n = 3 and at least one X = Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile); (l) n = 3 and at least two X = Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile); (m) n = 2 and each X = Ala or Gly;(h) n = 3 and each X = Ala or Gly;(o) n = 3 and at least one X = Ala or Gly (with the residue(s) (s) remaining amino acid X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile); or (p) n = 3 and at least two X = Ala or Gly (with the remaining amino acid residue(s) X being independently chosen from any naturally occurring amino acid, but preferably being independently chosen from Val, Leu and/or Ile);
[0095] with aspects (a), (b), (c), (g), (h), (i), (m) and (n) being particularly preferred, with aspects in which n = 1 or 2 are preferred and aspects where n = 1 are particularly preferred.
[0096] It should also be noted that preferably any C-terminal extension present in a CTLA4 ligand (eg, ISVD as a Nanobody) of the invention does not contain a (free) cysteine residue, except where noted Cysteine residue is used or intended for further functionalization, eg for PEGylation.
Some specific but non-limiting examples of useful C-terminal extensions are the following amino acid sequences: A, AA, AAA, G, GG, GGG, AG, GA, AAG, AGG, AGA, GGA, GAA or GAG.
When CTLA4 binders (e.g., ISVD as a Nanobody) of the invention contain mutations at positions 110 or 112 (optionally in combination with mutations at position 1, 11, 14, 45, 74, 83, 89, 96 and /or 108 as described herein) (with respect to the amino acid sequence of SEQ ID NO: 1), the C-terminal amino acid residues of framework 4 (starting from position 109) may be, in one embodiment of the invention, as shown in SEQ ID NO: 1, but wherein the 5 C-terminal residues can be substituted as set out below: (i) if no C-terminal extension is present: VTVKS (SEQ ID NO: 45), VTVQS ( SEQ ID NO: 46), VKVSS (SEQ ID NO: 47) or VQVSS (SEQ ID NO: 48); or (j) ) if a C-terminal extension is present: VTVKSX(n)(SEQ ID NO:49), VTVQSX(n) (SEQ ID NO:50), VKVSSX(n) (SEQ ID NO:51) or VQVSSX(n)(SEQ ID NO: 52), such as VTVKSA (SEQ ID NO: 53), VTVQSA (SEQ ID NO: 54), VKVSSA (SEQ ID NO: 55) or VQVSSA (SEQ ID NO: 56).
[0099] When CTLA4 binders (eg ISVD as a Nanobody) of the invention do not contain mutations at positions 110 or 112 (but only mutations at position 1, 11, 14, 45, 74, 83, 89, 96 and/ or 108 as described herein), the C-terminal amino acid residues of framework 4 (starting from position 109) may be, in one embodiment of the invention, as shown in SEQ ID NO: 1, but wherein the 5 residues C-terminals may be substituted as set out below:(i) when no extension of the C-terminal is present: VTVSS (SEQ ID NO:57) (as per the sequence of SEQ ID NO: 1); or (ii) when a C-terminal extension is present: VTVSSX(n) (SEQ ID NO: 58) as VTVSSA (SEQ ID NO: 59). In these C-terminal sequences, X and n are as defined herein for the C-terminal extensions.
Some preferred, but non-limiting, examples of CTLA4 binders (e.g., ISVD as a Nanobody) of the invention are given in SEQ ID NOs: 9-43 and 60, and each such sequence forms a further aspect of the invention (according to proteins, CTLA4 ligands, polypeptides or other compounds or constructs that comprise one of these sequences). Among these, the CTLA4 linkers of SEQ ID NOs: 9 to 25 and 60 do not have a C-terminal extension, and the CTLA4 linkers of SEQ ID NOs: 26 to 43 contain a C-terminal alanine (which is an example preferred, but not limiting, of a C-terminal extension as described herein).
Examples of CTLA4 binders (e.g. ISVD as a Nanobody) of the invention comprise the amino acid sequences of SEQ IDNOs: 22, 23, 24, 25, 40, 41, 42, 43 and 60.
[00102] Thus, in a first aspect, the invention relates to a CTLA4 binder (for example, a single variable domain of immunoglobulin as a Nanobody) which has: FYGMG (SEQ ID NO: 2); and DIRTSAGRTYYADSVKG (SEQ ID NO: 3); and EPSGISGWDY (SEQ ID NO:4); and which has:SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any extent of the C-terminal that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for the determination of sequence identity degree) when the comparison is performed by a BLAST algorithm, where the algorithm parameters are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (e.g., expected threshold: 10; word length: 3; maximum correlations in a query range: 0; BLOSUM 62 matrix; gap costs: existence 11, extension 1; conditional compositional scoring matrix adjustment); and/or- no more than 7, like no more than 5, preferably no more than 3, like just 3, 2 or 1" amino acid difference gone" (as defined herein, and not taking into account any of the mutations listed above in position (or positions) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/ or 112 which may be present and not taking into account any C-terminal extension which may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or in the CDRs, but are preferably present only in the structures and not in the CDRs); and optionally having:- a (X)n C-terminal extension, where n is 1 to 10, of preferably 1 to 5 as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I); wherein, in the amino acid sequence of the CTLA4 linker: - the amino acid residue at position 1 is preferably chosen from E or D; - the amino acid residue at position 11 is preferably chosen from L or V; - the amino acid residue at position 14 is preferably chosen from A or P; - the amino acid residue at position 45 is preferably chosen from of Q or R; - the amino acid residue at position 74 is preferably chosen from A or S; - the amino acid residue at position 83 is preferably chosen from K or R; - the amino acid residue at position 89 is preferably suitably chosen from T, V or L; - the amino acid residue at position 96 is preferably chosen from M or P; - the amino acid residue at position 108 is preferably chosen from Q or L; the amino acid residue at position 110 is preferably suitably chosen from T, K or Q; and/or- the amino acid residue at position 112 is preferably suitably chosen from S, K or Q; such that, for example, one or more of the following is true: (i) position 1 is E or D;(ii) position 11 is V;(iii) position 14 is P;(iv) position 45 is R;(v) position 74 is S;(vi) position 83 is R;(vii) position 89 is T or L; (viii) position 96 is P; (ix) position 108 is L; and/or for example, wherein the CTLA4 ligand comprises one or more of the sets of mutations below. position 11 is V and position 110 is K or Q; B. position 11 is V and position 112 is K or Q.c. position 89 is L and position 11 is V;d. position 89 is L and position 110 is K or Q;e. position 89 is L and position 112 is K or Q;f. position 89 is L and position 11 is V and position 110 is K or Q;g. position 89 is L and position 11 is V and position 112 is K or Q;h. position 1 is E or D; position 11 is V; position 14 is P; position 45 is R; position 74 is S; position 83 is R; position 89 is L; position 96 is P; and position 108 is L;i. position 1 is E or D; position 11 is V; position 14 is P; position 45 is R; position 74 is S; position 83 is R; position 89 is L; position 96 is P; position 108 is L; and position 110 is K or Q;j. position 1 is E or D; position 11 is V; position 14 is P; position 45 is R; position 74 is S; position 83 is R; position 89 is L; position 96 is P; position 108 is L; and position 112 is K or Q;k. position 1 is E or D; position 11 is V; position 14 is P; position 45 is R; position 74 is S; position 83 is R; position 89 is L; position 96 is P; and position 108 is L.
[00103] In a further aspect, the invention relates to a CTLA4 linker (for example a single immunoglobulin variable domain such as a Nanobody) which has: FYGMG (SEQ ID NO: 2); and DIRTSAGRTYYADSVKG (SEQ ID NO: 3); and EPSGISGWDY (SEQ ID NO:4); and which has: SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any extent of C-terminal that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for the determination of sequence identity degree) when the comparison is performed by a BLAST algorithm, where the algorithm parameters are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (e.g., expected threshold: 10; word length: 3; maximum correlations in a query range: 0; BLOSUM 62 matrix; gap costs: existence 11, extension 1; conditional compositional scoring matrix adjustment); and/or- no more than 7, such as no more than 5, preferably no more than 3, such as only 3, 2 or 1 "amino acid difference" (as defined herein, and not taking into account any one of the mutations listed above at position (or positions) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not taking into account any extension of the C -terminal which may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or the CDRs, but are preferably present only in the structures and not in the CDRs); and optionally having:- an extension of the C-terminal (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 ( and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I); such a CTLA4 linker (e.g., a single immunoglobulin variable domain such as a Nanobody) comprises one or more of the following amino acid residues (i.e., mutations compared to the amino acid sequence of SEQ ID NO: 1) at the mentioned positions (numbering according to Kabat): - 1D or 1E; - 11V; - 14P; - 45R; - 74S; - 83R; - 89T or - 89L; - 96P; or - 108L;
[00104] for example, wherein the CTLA4 ligand comprises one or more of the sets of mutations below:- 1D or 1E in combination with 11V; 14P; 45R; 74S; 83R; 89L; 96P; and 108L; - 11V in combination with 110K or 110Q; - 11V in combination with 112K or 112Q; - 89L in combination with 11V; - 89L in combination with 110K or 110Q; - 89L in combination with 112K or 112Q; - 1D or 1E in combination with 11V; 14P; 45R; 74S; 83R; 89L; 96P; 108L and 110K or 110Q;- 1D or 1E in combination with 11V; 14P; 45R; 74S; 83R; 89L; 96P; 108L and 112K or 112Q;- 89L in combination with 11V and 110K or 110Q; or - 89L in combination with 11V and 112K or 112Q;
[00105] As mentioned, when a CTLA4 linker (eg ISVD as a Nanobody) of the invention is used in a monovalent format and/or where the CTLA4 binding moiety is present at the C-terminal end of a linker to CTLA4 of the invention (as defined herein), the CTLA4 linker preferably has an X(n) C-terminal extension, such C-terminal extension may be as described herein for CTLA4 linkers of invention and/or as described in document under no. WO 2012/175741 or PCT/EP2015/060643 (WO2015/173325).
[00106] Some preferred, but non-limiting, examples of CTLA4 binders (e.g., ISVD as a Nanobody) of the invention are given in SEQ ID NOs: 8 to 43 or 60, and each of these amino acid sequences individually forms an aspect addition of the invention.
[00107] As mentioned, in the invention, the amino acid sequences where position 89 is T; or where 1-position is E or D, 11-position is V, 14-position is P, 45-position is R, 74-position is S, 83-position is R, 89-position is L, 96-position is P and position 108 is L; or where position 11 is V and position 89 is L (optionally in suitable combination with a 110K or 110Q mutation and/or a 112K or 112Q mutation, and in particular in combination with a 110K or 110Q mutation) are particularly preferred. Even more preferred are amino acid sequences where position 11 is V and position 89 is L, optionally with a 110K or 110Q mutation.
[00108] Thus, in a preferred aspect, the invention relates to a CTLA4 ligand (for example, a single immunoglobulin variable domain as a Nanobody) which has: - a CDR1 (according to Kabat) which is the sequence amino acid FYGMG (SEQ ID NO: 2); and - a CDR2 (according to Kabat) which is the amino acid sequence DIRTSAGRTYYADSVKG (SEQ ID NO: 3); and- a CDR3 (according to Kabat) which is the amino acid sequence EPSGISGWDY (SEQ ID NO:4); and which has:- a degree of sequence identity with the amino acid sequence of SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, in which the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; wordlength: 3; maximum correlations in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; composite score matrix adjustment conditional onal); and/or- no more than 7, such as no more than 5, preferably no more than 3, such as only 3, 2 or 1 "amino acid difference" (as defined herein, and not leading to take into account any of the mutations listed above in position (or positions) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not taking into account any C-terminal extension that may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or the CDRs, but are present, of preferably only in the structures and not in the CDRs); and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I);
[00109] wherein, in the amino acid sequence of the CTLA4 linker: - the amino acid residue at position 1 is preferably chosen from E or D; - the amino acid residue at position 11 is preferably chosen from L or V; - the amino acid residue at position 14 is preferably chosen from A or P; - the amino acid residue at position 45 is preferably chosen from Q or R; the amino acid residue at position 74 is preferably chosen from A or S; - the amino acid residue at position 83 is preferably chosen from K or R; - the amino acid residue at position 89 is preferably chosen from T, L or V; - the amino acid residue at position 96 is preferably chosen from M or P; - the amino acid residue at position 108 is preferably chosen a from L or Q; the amino acid residue at position 110 is preferably suitably chosen from T, K or Q (and is preferably T); and/or- the amino acid residue at position 112 is preferably suitably chosen from S, K or Q (and is preferably S).
[00110] In another preferred aspect, the invention relates to a CTLA4 linker (for example a single immunoglobulin variable domain such as a Nanobody) which has:- a CDR1 (according to Kabat) which is the amino acid sequence FYGMG (SEQ ID NO: 2); and - a CDR2 (according to Kabat) which is the amino acid sequence DIRTSAGRTYYADSVKG (SEQ ID NO: 3); and- a CDR3 (according to Kabat) which is the amino acid sequence EPSGISGWDY (SEQ ID NO:4); and which has:- a degree of sequence identity with the amino acid sequence of SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, in which the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; wordlength: 3; maximum correlations in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; composite score matrix adjustment conditional onal); and/or- no more than 7, such as no more than 5, preferably no more than 3, such as only 3, 2 or 1 "amino acid difference" (as defined herein, and not leading to take into account any of the mutations listed above in position (or positions) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not taking into account any C-terminal extension that may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or the CDRs, but are present, of preferably only in the structures and not in the CDRs); and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I);
[00111] wherein, for example, the CTLA4 linker comprises one or more mutations according to the following:- the amino acid residue at position 1 is E or D;- the amino acid residue at position 11 is V;- o amino acid residue at position 14 is P;- amino acid residue at position 45 is R;- amino acid residue at position 74 is S;- amino acid residue at position 83 is R;- amino acid residue at position 89 is L;- the amino acid residue at position 96 is P; - the amino acid residue at position 108 is L; - the amino acid residue at position 110 is preferably chosen from T, K or Q; or - the amino acid residue at position 112 is preferably chosen from S, K or Q.
[00112] In a specific, but not limiting, aspect, the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention comprise the one or more of the following sets of mutations (i.e. mutations compared to the SEQ sequence ID NO: 1) at the mentioned positions (numbering according to Kabat): - 11V in combination with 89L; - 11V in combination with 110K or 110Q; - 11V in combination with 112K or 112Q; - 11V in combination with 89L and 110K or 110Q;- 11V in combination with 89L and 112K or 112Q; - 11V in combination with 1D or 1E, 14P, 45R, 74S, 83R, 89L, 96P, 108L and 110K or 110Q; - 11V in combination with 1D or 1E, 14P, 45R, 74S, 83R, 89L, 96P, 108L and 112K or 112Q; or- 11V in combination with 1D or 1E, 14P, 45R, 74S, 83R, 89L, 96P and 108L. and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Kabat) and have a full degree of sequence identity with the sequence of amino acids of SEQ ID NO: 1, which are as described herein.
[00113] In another specific, but non-limiting aspect, the CTLA4 binders (for example, ISVD as a Nanobody) of the invention comprise one or more of the following sets of mutations (i.e. mutations compared to the SEQ sequence ID NO: 1) in the mentioned positions (numbering according to Kabat): - 89L in combination with 11V; - 89L in combination with 110K or 110Q; - 89L in combination with 112K or 112Q; - 89L in combination with 11V and 110K or 110Q; - 89L in combination with 11V and 112K or 112Q; - 89L in combination with 1D or 1E, 11V, 14P, 45R, 74S, 83R, 96P and 108L; - 89L in combination with 1D or 1E, 11V, 14P, 45R , 74S, 83R, 96P, 108L and 110K or 110Q; or - 89L in combination with 1D or 1E, 11V, 14P, 45R, 74S, 83R, 96P, 108L and 112K or 112Q, and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Kabat) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00114] In another specific, but non-limiting aspect, the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention comprise one or more of the following amino acid sets of mutations (i.e. mutations compared to sequence of SEQ ID NO: 1) at the mentioned positions (numbering according to Kabat): - 110K or 110Q in combination with 11V; - 110K or 110Q in combination with 89L; - 110K or 110Q in combination with 11V and 89L; - 110K or 110Q in combination with 1D or 1E, 11V, 14P, 45R, 74S, 83R, 89L, 96P and 108L.e have CDRs that are in a CTLA4 linker of Table A, for example in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Kabat) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00115] In another specific, but non-limiting aspect, the CTLA4 binders (for example, ISVD as a Nanobody) of the invention comprise one or more of the following sets of mutations (i.e. mutations compared to the SEQ sequence ID NO: 1) at the mentioned positions (numbering according to Kabat): - 112K or 112Q in combination with 11 V; - 112K or 112Q in combination with 89L; or - 112K or 112Q in combination with 11V and 89L; or- 112K or 112Q in combination with 1D or 1E, 11V, 14P, 45R, 74S, 83R, 89L, 96P and 108L. and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Kabat) and have a full degree of sequence identity with the sequence of amino acids of SEQ ID NO: 1, which are as described herein.
[00116] In another aspect, the CTLA4 binders (for example, ISVD as a Nanobody) of the invention comprise a T at position 89 and have CDRs like those shown in SEQ ID NO: 60 (for example, according to Kabat) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00117] In another aspect, the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention comprise a V at position 11 and an L at position 89 and have CDRs like those shown in SEQ ID NO: 1 or 60 ( for example, according to Kabat) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00118] As mentioned, the CTLA4 ligands (eg ISVD as a Nanobody) of the invention according to the above aspects further preferably contain a suitable combination of an E1D mutation, L11V mutation, A14P mutation, a mutation Q45R, an A74S mutation, a K83R mutation, a V89L mutation, an M96P mutation and a Q108L mutation and, in one embodiment of the invention, a suitable combination of Q108L with any of the other mutations A14P, Q45R, A74S and K83R, and , in one embodiment of the invention, in combination with any two of these other mutations, more preferably with any three of these mutations (as with the A14P, A74S and K83R combination), as with all four of these mutations (and again, when the CTLA4 linker is monovalent or is present at the N-terminal end of a CTLA4 linker of the invention, preferably also a mutation in E1D).
[00119] In another aspect, the invention relates to a CTLA4 linker (for example a single immunoglobulin variable domain like a Nanobody) which has:- a CDR1 (according to Abm) which is the amino acid sequence GGTFSFYGMG (SEQ ID NO: 5); e- a CDR2 (according to Abm) which is the amino acid sequence DIRTSAGRTY (SEQ ID NO: 6); and- a CDR3 (according to Abm) which is the amino acid sequence EPSGISGWDY (SEQ ID NO:4); and which has:- a degree of sequence identity with the amino acid sequence of SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, in which the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; wordlength: 3; maximum correlations in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; composition score matrix adjustment conditional al); and/or- no more than 7, as no more than 5, preferably no more than 3, as only 3, 2 or 1 "amino acid difference" (as defined herein, and not leading to take into account any of the mutations listed above in position (or positions) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not taking into account any C-terminal extension that may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or the CDRs, but are present, of preferably only in the structures and not in the CDRs); and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I); which comprises an amino acid sequence wherein:- the amino acid residue at position 1 is E or D;- the amino acid residue at position 11 is L or V; - the amino acid residue at position 14 is P; - the amino acid residue at position 45 is R; - the amino acid residue at position 74 is S; - the amino acid residue at position 83 is R; - the amino acid residue at position 89 is preferably chosen from T, V or L; - the amino acid residue at position 96 is P; - the amino acid residue at position 108 is L; - the amino acid residue at position 110 is from preferably, chosen from T, K or Q; e- the amino acid residue at position 112 is preferably chosen from S, K or Q; for example, so that one or more of the following is true: (i) position 1 is D or E;( ii) position 11 is V; (iii) position 14 is P; (iv) position 45 is R; (v) position 74 is S; (vi) position 83 is R; (vii) position 89 is L or T;( viii) position 96 is P; or (ix) position 108 is L. e.g. where the CTLA4 linker comprises one or more of the sets of mutations below:a. position 11 is V and position 110 is K or Q;b. position 11 is V and position 112 is K or Q;c. position 89 is L and position 11 is V; d. position 89 is L and position 110 is K or Q;e. position 89 is L and position 112 is K or Q;f. position 89 is L and position 11 is V and position 110 is K or Q; org. position 89 is L and position 11 is V and position 112 is K or Q.
[00120] In a further aspect, the invention relates to a CTLA4 linker (for example a single immunoglobulin variable domain like a Nanobody) which has:- a CDR1 (according to Abm) which is the amino acid sequence GGTFSFYGMG (SEQ ID NO: 5); e- a CDR2 (according to Abm) which is the amino acid sequence DIRTSAGRTY (SEQ ID NO: 6); and- a CDR3 (according to Abm) which is the amino acid sequence EPSGISGWDY (SEQ ID NO:4); and which has:- a degree of sequence identity with the amino acid sequence of SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, in which the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; wordlength: 3; maximum correlations in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; composition score matrix adjustment conditional al); and/or- no more than 7, such as no more than 5, preferably no more than 3, such as only 3, 2 or 1 "amino acid difference" (as defined herein, and not taking into account any one of the mutations listed above in position(s) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not taking into account any extension of the C-terminal which may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or in the CDRs, but are preferably present, only in the structures and not in the CDRs); and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I); which CTLA4 linker (for example, a single immunoglobulin variable domain such as a Nanobody) comprises one or more of the following amino acid residues (i.e. mutations compared to the amino acid sequence of SEQ ID NO: 1) at the mentioned positions (numbering according to Kabat): - 1D or 1E; - 11V; - 14P; - 45R; - 74S; - 83R; - 89L or 89T; - 96P; or - 108L; for example, wherein the CTLA4 ligand comprises one or more of the sets of mutations below: - 11V in combination with 110K or 110Q; - 11V in combination with 112K or 112Q; - 89L in combination with 11V;- 89L in combination with 110K or 110Q;- 89L in combination with 112K or 112Q;- 89L in combination with 11V and 110K or 110Q; or- 89L in combination with 11V and 112K or 112Q.
[00121] As mentioned, when a CTLA4 linker (eg ISVD as a Nanobody) of the invention is used in a monovalent format and/or where the CTLA4 binding moiety is present at the C-terminal end of a linker to CTLA4 of the invention (as defined herein), the CTLA4 linker preferably has an X(n) C-terminal extension, such C-terminal extension may be as described herein for CTLA4 linkers of invention and/or as described in WO 2012/175741 or PCT/EP2015/060643 (WO2015/173325).
[00122] Some preferred, but non-limiting, examples of CTLA4 binders (e.g., ISVD as a Nanobody) of the invention are given in SEQ ID NOs: 8 to 43 and 60, and each of these amino acid sequences individually forms an aspect addition of the invention.
[00123] As mentioned, in the invention, the amino acid sequences where position 89 is T; or where 1-position is E or D, 11-position is V, 14-position is P, 45-position is R, 74-position is S, 83-position is R, 89-position is L, 96-position is P or position 108 is L; or where position 11 is V and position 89 is L (optionally in suitable combination with a 110K or 110Q mutation and/or a 112K or 112Q mutation, and in particular in combination with a 110K or 110Q mutation) are particularly preferred. Even more preferred are amino acid sequences where position 11 is V and position 89 is L, optionally with a 110K or 110Q mutation.
[00124] Thus, in a preferred aspect, the invention relates to a CTLA4 ligand (for example, a single immunoglobulin variable domain as a Nanobody) which has:- a CDR1 (according to Abm) which is the sequence amino acid GGTFSFYGMG (SEQ ID NO: 5); e- a CDR2 (according to Abm) which is the amino acid sequence DIRTSAGRTY (SEQ ID NO: 6); and- a CDR3 (according to Abm) which is the amino acid sequence EPSGISGWDY (SEQ ID NO:4); and which has:- a degree of sequence identity with the amino acid sequence of SEQ ID NO:1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, in which the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; wordlength: 3; maximum correlations in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; composition score matrix adjustment conditional al); and/or- no more than 7, as no more than 5, preferably no more than 3, as only 3, 2 or 1 "amino acid difference" (as defined herein, and not leading to take into account any of the mutations listed above in position(s) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not leading to count any C-terminal extension that may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or in the CDRs, but are present, preferably only in the structures and not in the CDRs); and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3 , 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I); which comprises an amino acid sequence which has one or more mutations (with respect to the amino acid sequence of SEQ ID NO: 1) according to the following:- the amino acid residue at position 1 is preferably chosen from E and D; - the amino acid residue at position 11 is preferably chosen from L and V; - the amino acid residue at position 14 is preferably chosen from A and P; - the amino acid residue at position 45 is preferably chosen from Q and R; - the amino acid residue at position 74 is preferably chosen from A and S; - the residue of amino acid at position 83 is preferably chosen from K and R; - amino acid residue at position 89 is preferably chosen. from T, L and V; - the amino acid residue at position 96 is preferably chosen from M or P; - the amino acid residue at position 108 is preferably chosen from L or Q;- the amino acid residue at position 110 is preferably chosen from T, K or Q (and is preferably T); e- the amino acid residue at position 112 is preferably chosen from S, K or Q (and preferably S).
[00125] In another preferred aspect, the invention relates to a CTLA4 linker (for example, a single immunoglobulin variable domain such as a Nanobody) which has:- a CDR1 (according to Abm) which is the amino acid sequence GGTFSFYGMG (SEQ ID NO: 5); e- a CDR2 (according to Abm) which is the amino acid sequence DIRTSAGRTY (SEQ ID NO: 6); and - a CDR3 (according to Abm) which is the amino acid sequence EPSGISGWDY (SEQ ID NO: 4); and which has: - a degree of sequence identity with the amino acid sequence of SEQ ID NO: 1 of at least 85%, preferably at least 90%, more preferably at least 95% (wherein the CDRs, any C-terminal extension that may be present, as well as mutations at positions 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 required by the specific aspect involved are not taken into account for determining the degree of sequence identity) when the comparison is performed by a BLAST algorithm, in which the parameters of the algorithm are selected to generate the highest correlation between the respective sequences over the entire length of the respective reference sequences (eg, expected threshold: 10; wordlength: 3; maximum correlations in a query range: 0; matrix BLOSUM 62; gap costs: existence 11, extension 1; composition score matrix adjustment conditional nal); and/or- no more than 7, as no more than 5, preferably no more than 3, as only 3, 2 or 1 "amino acid difference" (as defined herein, and not leading to take into account any of the mutations listed above in position(s) 1, 11, 14, 45, 74, 83, 89, 96, 108, 110 and/or 112 that may be present and not taking up into account any C-terminal extension that may be present) with the amino acid sequence of SEQ ID NO: 1 (wherein said amino acid differences, if present, may be present in the structures and/or in the CDRs, but are present preferably only in the structures and not in the CDRs; and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I); wherein the CTLA4 linker comprises one or more of the following mutations:- the amino acid residue at position 1 is D or E;- the amino acid residue at position 11 is V; amino acid residue at position 14 is P;- amino acid residue at position 45 is R;- amino acid residue at position 74 is S;- amino acid residue at position 83 is R;- amino acid residue at position 89 is L;- the amino acid residue at position 96 is P;- the amino acid residue at position 108 is L;- the amino acid residue at position 110 is preferably suitably chosen from T, K or Q; or - the amino acid residue at position 112 is preferably suitably chosen from S, K or Q.
[00126] In a specific, but not limiting, aspect, the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention comprise the one or more of the following sets of mutations (i.e. mutations compared to the SEQ sequence ID NO: 1) at the mentioned positions (numbering according to Kabat): - 11V in combination with 89L; - 11V in combination with 1D, 14P, 45R, 74S, 83R, 89L, 96P, 108L; - 11V in combination with 1E , 14P, 45R, 74S, 83R, 89L, 96P, 108L; - 11V in combination with 110K or 110Q; - 11V in combination with 110K or 110Q, and 1D or 1E and 14P, 45R, 74S, 83R, 89L, 96P and 108L; - 11V in combination with 112K or 112Q; - 11V in combination with 112K or 112Q, and 1D or 1E and 14P, 45R, 74S, 83R, 89L, 96P and 108L; - 11V in combination with 89L and 110K or 110Q; or - 11V in combination with 89L and 112K or 112Q, and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Abm) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00127] In another specific, but non-limiting aspect, the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention comprise the following sets of mutations (i.e. mutations compared to the sequence of SEQ ID NO: 1 ) in the mentioned positions (numbering according to Kabat): - 89L in combination with 11V; - 89L in combination with 1D or 1E, 11V, 14P, 45R, 74S, 83R, 96P and 108L; - 89L in combination with 110K or 110Q; - 89L in combination with 110K or 110Q and 1D or 1E and 11V, 14P, 45R , 74S, 83R, 96P and 108L; - 89L in combination with 112K or 112Q; - 89L in combination with 112K or 112Q and 1D or 1E and 11V, 14P, 45R, 74S, 83R, 96P and 108L; - 89L in combination with 11V and 110K or 110Q; or - 89L in combination with 11V and 112K or 112Q; and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Abm) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00128] In another specific but non-limiting aspect, the CTLA4 binders (e.g., ISVD as a Nanobody) of the invention comprise the following sets of mutations (i.e. mutations compared to the sequence of SEQ ID NO: 1 ) in the mentioned positions (numbering according to Kabat): - 110K or 110Q in combination with 11V; - 110K or 110Q in combination with 89L; - 110K or 110Q in combination with 11V and 89L; or - 110K or 110Q in combination with 1D or 1E and 11V, 14P, 45R, 74S, 83R, 89L, 96P and 108L, and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Abm) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00129] In another specific, but non-limiting aspect, the CTLA4 binders (for example, ISVD as a Nanobody) of the invention comprise the following sets of mutations (i.e. mutations compared to the sequence of SEQ ID NO: 1 ) in the mentioned positions (numbering according to Kabat): - 112K or 112Q in combination with 11V; - 112K or 112Q in combination with 89L; - 112K or 112Q in combination with 11V and 89L; or - 112K or 112Q in combination with 1D or 1E and 11V, 14P, 45R, 74S, 83R, 89L, 96P and 108L, and have CDRs that are in a CTLA4 linker of Table A, for example, in SEQ ID NO: 1 or SEQ ID NO: 60 (for example, according to Abm) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00130] In another aspect, the CTLA4 binders (for example, ISVD as a Nanobody) of the invention comprise a T at position 89 and have CDRs like those shown in SEQ ID NO: 1 or 60 (for example, according to Abm) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00131] In another aspect, the CTLA4 binders (for example, ISVD as a Nanobody) of the invention comprise a V at position 11 and an L at position 89 and have CDRs like those shown in SEQ ID NO: 60 (for example , according to Abm) and have a full degree of sequence identity with the amino acid sequence of SEQ ID NO: 1, which are as described herein.
[00132] As mentioned, CTLA4 ligands (eg ISVD as a Nanobody) of the invention according to the above aspects are preferably additionally such that they contain a suitable combination of an optional E1D mutation, an L11V mutation , A14P mutation, a Q45R mutation, an A74S mutation, a K83R mutation, a V89L mutation, an M96P mutation, and a Q108L mutation, and preferably, a suitable combination of Q108L with any of the other mutations A14P, Q45R, A74S and K83R, and preferably in combination with any two of these other mutations, more preferably with any three of these mutations (as with the A14P, A74S and K83R combination), as with all of these mutations (and again, when the linker of CTLA4 is monovalent or is present at the N-terminal end of a CTLA4 linker of the invention, preferably also a mutation in E1D). In one embodiment of the invention, the CTLA4 binders of the present invention comprise the E1D mutations (or are devoid of such a mutation, wherein residue 1 is E), L11V, A14P, Q45R, A74S, K83R, V89L, M96P, Q108L.
[00133] In another specific, but not limiting, aspect, the invention relates to a CTLA4 linker (for example, a single immunoglobulin variable domain such as a Nanobody) which is or consists essentially of an amino acid sequence chosen from a from the following amino acid sequences: SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO :23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 or SEQ ID NO: 60.
[00134] In another specific, but not limiting, aspect, the invention relates to a CTLA4 linker (for example, a single immunoglobulin variable domain such as a Nanobody) which is or consists essentially of an amino acid sequence chosen from a from the following amino acid sequences: SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 or SEQ ID NO: 60.
[00135] Furthermore, as already indicated herein, the amino acid residues of a CTLA4 linker (for example, an ISVD such as a Nanobody) are numbered according to the general numbering for VHs given by Kabat et al. ("Sequence of proteins of immunological interest," US Public Health Services, NIH Bethesda, MD, publication no. 91), as applied to VHH domains from camelids in an article by Riechmann and Muyldermans, J. Immunol. Methods 2000 Jun 23; 240 (1-2): 185 to 195; or mentioned in this document. It should be noted that, as is well known in the art for VH domains and for VHH domains, the total number of amino acid residues in each of the CDRs may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering (that is, one or more positions according to Kabat numbering may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed by Kabat numbering). This means that, in general, the numbering according to Kabat may or may not correspond to the actual numbering of the amino acid residues in the actual sequence.
[00136] Alternative methods for numbering the amino acid residues of VH domains, such methods can also be applied in an analogous manner to VHH domains from camelids and to Nanobodies, is the method described by Chothia et al. (Nature 342, 877 to 883 (1989)), the so-called "AbM definition" and the so-called "contact definition". However, in the present description, aspects and figures, numbering according to Kabat as applied to VHH domains by Riechmann and Muyldermans will be followed, except where otherwise indicated.
[00137] The invention also relates to CTLA4 ligands (for example, ISVD as a Nanobody); to methods for expressing/producing the CTLA4 ligands of the invention; to compositions and products (such as pharmaceutical products and compositions) comprising the CTLA4 binders of the invention; to polynucleotides encoding the CTLA4 binders of the invention; and to uses (and, in particular, therapeutic, prophylactic and diagnostic uses) of the CTLA4 ligands of the invention. These and other aspects, embodiments, advantages, applications and uses of the invention will become apparent from the further description herein.
[00138] Accordingly, in a further aspect, the invention relates to polypeptides or other chemical entities that comprise or consist essentially of at least one (such as one, two or three) CTLA4 binding moiety described herein. Such molecules themselves may be referred to as "CTLA4 ligands" or "compounds of the invention" or "polypeptides of the invention".
The CTLA4 linkers (eg ISVD as a Nanobody) of the invention may contain one or more other amino acid sequences, chemical entities or chemical moieties. Such other amino acid sequences, chemical entities or chemical moieties may confer one or more desired properties to the CTLA4 binders resulting from the invention and/or may alter the properties of the CTLA4 binders resulting from the invention in a desired manner, e.g., to provide the resulting CTLA4 ligands of the invention with a desired biological and/or therapeutic activity (for example, to provide the resulting CTLA4 ligands of the invention with affinity and, preferably, potency against another therapeutically relevant target, such that the resulting polypeptide becomes "bispecific" with respect to CTLA4 and that another therapeutically relevant target such as PD1, LAG3, BTLA and/or CD27), to provide a desired half-life and/or to otherwise modify or improve pharmacokinetic and/or pharmacodynamic properties , to target the CTLA4 ligand to specific cells, tissues or organs (including cancer cells and cancer tissues). enos) to provide a cytotoxic effect and/or to serve as a detectable identifier or marker. Some non-limiting examples of such other amino acid sequences, chemical entities or chemical moieties are: - one or more suitable linkers (such as a 9GS, 15GS or 35GS linker (any combination of 9, 15 or 35G and S amino acids such as for example , GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS)) (SEQ ID NO: 65). In one embodiment of the invention, the linker is (GGGGS)n(SEQ ID NO: 118), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.; and/or- one or more chemical binding moieties, binding domains or binding moieties that are directed against a therapeutically relevant target other than CTLA4 (i.e., in order to provide a CTLA4 ligand of the invention that is bispecific for both CTLA4 as for the other therapeutically relevant target, such as an epitope other than CTLA4, PD1, CD27, LAG3, BTLA, TIM3, ICOS, B7-H3, B7-H4, CD137, GITR, PD-L1, PD-L2, ILT1, ILT2 CEACAM1, CEACAM5, TIM3, TIGIT, VISTA, ILT3, ILT4, ILT5, ILT6, ILT7, ILT8, CD40, OX40, CD137, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL2, KIR3 NKG2E, IL-10, IL-17, TSLP)) and/or- one or more binding domains or binding units that provide for an increase in half-life (e.g., a binding domain or binding unit that can bind against a serum protein such as serum albumin); and/or- one or more chemical binding moieties, binding domains or binding moieties that direct the CTLA4 ligand (for example, ISVD as a Nanobody) to a desired cell, tissue or organ (such as a cancer cell); and/or one or more binding moieties, binding domains or binding moieties that provide increased specificity against CTLA4 (typically, these will have the ability to bind CTLA4, but in general, by themselves, essentially will not be functional against CTLA4 ); and/or a binding moiety, binding domain, binding moiety, or other chemical entity that allows the CTLA4 ligand to be internalized into a (desired) cell (e.g., an internalizing anti-EGFR Nanobody, as described in WO 2005/044858) ); and/or a half-life enhancing moiety such as a suitable polyethylene glycol group (i.e., PEGylation) or an amino acid sequence that provides a suitable half-life such as human serum albumin or a suitable fragment thereof (i.e., fusion of albumin) or, for example, a serum albumin binding peptide as described in WO 2008/068280; and/or- a payload such as a cytotoxic payload; and/or- a detectable label or label, such as a radiolabel or fluorescent label; and/or- a tag that can help with the immobilization, detection and/or purification of the CTLA4 ligand, such as a HIS or FLAG3 tag; and/or- a marker that can be functionalized, such as a C-terminal GGC or GGGC marker; and/or an extension of the C-terminal X(n) which may be as further described herein for the CTLA4 binders of the invention and/or as described in the document under WO 2012/175741 or PCT/EP2015/060643 ( WO2015/173325).
CTLA4 binders (eg ISVD as a Nanobody) which also contain one or more parts or fragments of a conventional (preferably human) antibody (such as an Fc part, a functional fragment thereof, or one or more constant domains) and/or from a heavy-chain camelid-only antibody (as one or more constant domains) are part of the present invention.
[00141] The present invention includes CTLA4 ligands that can be fused into a single multivalent (e.g., multispecific) molecule that also binds to CTLA4 or another polypeptide and, in one embodiment of the invention, such ligands are linked to a or more half-life-extending agents that increase the half-life of the linkers in an individual's body (e.g., comprising the amino acid sequence shown in SEQ ID NO: 62 or 64). In one embodiment of the invention, the half-life extender is an ISVD (eg a Nanobody) that specifically binds to human serum albumin (HSA), eg ALB11002. In one embodiment of the invention, the multispecific linker is F023700912 or F023700914 as described herein.
[00142] A polypeptide can be "fused to" another molecule directly, without a linker, or through a linker such as a peptide linker, eg, 35GS.
Multispecific ligands can include a CTLA4 ligand, as well as one or more ligands that bind to an additional antigen such as CD27, PD1, :LAG3, BTLA, TIM3, ICOS, B7-H3, B7-H4, CD137, GITR, PD-L1, PD-L2, ILT1, ILT2 CEACAM1, CEACAM5, TIM3, TIGIT, VISTA, ILT3, ILT4, ILT5, ILT6, ILT7, ILT8, CD40, OX40, CD137, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KTR2DL4 ,KTR2DL5B, KTR3DL1, KIR3DL2, KTR3DL3, NKG2A, NKG2C, NKG2E, IL-10, IL-17 or TSLP.
[00144] For some specific examples, but not limiting, of such biological products based on ISVD or Nanobody based, reference is made to the various applications by Ablynx NV, such as, for example and without limitation, the documents under nos. 2004/062551, WO 2006/122825, WO 2008/020079 and WO 2009/068627, as well as for example, and without limitation, to applications such as documents under nos. WO 2006/038027, WO 2006/059108, WO 2007/063308 , WO 2007/063311, WO 2007/066016 and WO 2007/085814. Furthermore, as further described herein, an additional portion, which may be part of a molecule presented in the aforementioned applications, may be an ISVD or Nanobody as described herein, directed against a serum (human) protein such as serum albumin (human), and such ISVD or Nanobody (eg ALB11002) may also find therapeutic uses, in particular, in and/or to extend the half-life of CTLA4 ligands (and polypeptides comprising them) which are described in the this document. Reference is made, for example, to documents under nos. WO 2004/041865, WO 2006/122787 and WO 2012/175400, which describe in general the use of serum albumin binding Nanobodies for half-life extension. Document under No. WO 2009/138519 (or in the prior art cited in document under No. WO 2009/138519) or WO 2008/020079 (or in the prior art cited in document No. WO 2008/020079) is incorporated by reference. Furthermore, where a method or technique is not specifically described in this document, it may, in one embodiment of the invention, be carried out as described in the document under no. WO 2009/138519 (or in the prior art cited in the document under no. WO 2009/138519) or WO 2008/020079 (or in the prior art cited in document no. WO 2008/020079).
[00145] When CTLA4 linkers (for example ISVD as a Nanobody) contain one or more additional chemical binding moieties, binding domains or binding moieties (for example an additional essentially non-functional binding domain or binding moiety against CTLA4 which provides increased specificity against CTLA4, a binding moiety, binding domain or binding moiety against a therapeutic target other than CTLA4, a binding moiety, binding domain or binding moiety against a target such as human serum albumin increased half-life and/or a binding moiety, binding domain or binding unit which directs the CTLA4 ligand to a specific cell, tissue or organ and/or which allows the CTLA4 ligand to be internalized into a cell), such other chemical binding moieties, binding domains or binding moieties preferably comprise one or more ISVDs, and more preferably are all ISVDs. For example and without limitation, that one or more additional binding domains or binding moieties may be one or more Nanobodies (including a VHH, a humanized VHH and/or camelized VHs like camelized human VHs), an antibody (single domain) that is a VH domain or that is derived from a VH domain, a dAb that is or consists essentially of a VH domain or that is derived from a VH domain, or even a (single) domain antibody or a dAb that is or consists essentially of a VH domain in VL domain. In particular, such one or more binding domains or binding moieties, when present, may comprise one or more Nanobodies, and more particularly, they are all Nanobodies.
[00146] When a CTLA4 linker of the invention has an ISVD at its C-terminal end (such a C-terminal ISVD may be a CTLA4 binding moiety described herein or may be, for example, if present in the linker of CTLA4, an additional essentially non-functional ISVD against CTLA4 that provides increased specificity against CTLA4, an ISVD against a therapeutic target other than CTLA4, an ISVD against a target such as human serum albumin that provides increased half-life, or an ISVD that directs the ligand of CTLA4 to a specific cell, tissue or organ and/or which allows the CTLA4 ligand to be internalized into a cell), then the CTLA4 binding portion (i.e., said C-terminal ISVD) preferably has , an extension of the C-terminal X(n), such extension of the C-terminal can be as described herein for the CTLA4 binders of the invention and/or as described in the document under no. WO 2012/175741 or PCT/EP2015 /060643 (WO2015/173325).
[00147] When a CTLA4 linker (e.g., ISVD as a Nanobody) contains, in addition to one or more CTLA4 binding chemical moieties described herein, any additional ISVDs (such one or more additional ISVDs may be, as mentioned , an additional essentially non-functional ISVD against CTLA4 that provides increased specificity against CTLA4, an ISVD against a therapeutic target other than CTLA4, an ISVD against a target such as human serum albumin that provides increased half-life, and/or an ISVD that directs the ligand of CTLA4 to a specific cell, tissue or organ and/or which allows the CTLA4 ligand to be internalized into a cell), and wherein such additional ISVDs are Nanobodies or are ISVDs which are, consist essentially of and/or which are derived from VH sequences, then, according to a preferred aspect of the invention, said one or more (and preferably all) additional ISVDs present in the CTLA4 linker will contain within d and its sequence one or more framework mutations that reduce binding by pre-existing antibodies. In particular, according to that aspect of the invention, such additional ISVDs may contain (a suitable combination of) amino acid residues/mutations at positions 11, 89, 110 and/or 112 which are as described in the document under noPCT/EP2015/ 060643 (WO2015/173325) and/or which are essentially as described herein for the CTLA4 binders of the invention. In a specific aspect, when the CTLA4 ligand has such an ISVD at its C-terminal end (i.e., it has no CTLA4 binding portion of the invention at its C-terminal end), then at least said ISVD is present. in and/or form the C-terminal end has such framework mutations that reduce binding by pre-existing antibodies (and said C-terminal ISVD will also preferably have an extension of the C-terminal X(n) as described in this document).
[00148] As mentioned, when the CTLA4 ligand (eg ISVD as a Nanobody) should have an increased half-life (i.e., compared to the monovalent CTLA4 ligand of the invention), the CTLA4 ligand contains, of preferably, at least one (such as one(1)) ISVD (and, in particular, Nanobody) that provides such an increased half-life. Such ISVD will normally be directed against a suitable serum protein such as transferrin and, in particular, against serum albumin (human). In particular, such an ISVD or Nanobody may be a (single) domain antibody or dAb against human serum albumin, as described, for example, in documents under nos. EP 2 139 918, WO 2011/006915, WO 2012/175400, WO 2014/111550 and may in particular be a serum albumin binding Nanobody as described in documents under nos. WO 2004/041865, WO 2006/122787, WO 2012/175400 or PCT/EP2015/060643 (WO2015/173325). Particularly preferred serum albumin binding ISVDs are Nanobody Alb-1 (see document under WO 2006/122787) or humanized variants thereof as Alb-8 (WO 2006/122787, SEQ ID NO: 62), Alb- 23 (WO 2012/175400, SEQ ID NO: 1) and other humanized (and preferably also sequence-optimized) variants of Alb-1 and/or Alb-8 or Alb-23 variants (or more generally, ISVDs which they have essentially the same CDRs as Alb-1, Alb-8 and Alb-23).
[00149] In one embodiment of the invention, the ISVD (eg Nanobody) is ALB11002 which binds to human serum albumin. ALB11002 is summarized below in Table C.
[00150] The present invention includes CTLA4 binders that comprise an HSA binder of the invention, for example, that has the same combination of CDRs (i.e., CDR1, CDR2 and CDR3) that is present in ALB11002 or in a binder that comprises the sequence of SEQ ID NO: 66. See Table C. Table C. Human Serum Albumin Ligand (HSA) ALB11002

[00151] Optionally, ALB11002 is devoid of the C-terminal alanine. In one embodiment of the invention, the HSA linker comprises the amino acid sequence of SEQ ID NO: 66, but which includes a mutation at position 1, 1, 89, 110 or 112, for example, which comprises a set of mutations shown in Table C in this document.
[00152] Residue 1 of SEQ ID NO: 66 can be D or E. If residue 1 is D, the HSA linker can be designated as 1D and if residue 1 is E, the HSA linker can be designated as 1 AND.
[00153] The present invention includes HSA linkers comprising one, two or three CDRs of an HSA linker, each comprising 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, e.g., conservative substitutions, and/or comprises 100, 99, 98, 97, 96 or 95% sequence identity to the CDRs that are in the HSA linker sequences shown in Table C or are shown in SEQ ID NOs: 67 to 69, where an HSA linker that has such CDRs retains the ability to bind HSA.
In one embodiment of the invention, the half-life extender is an anti-HSA ISVD (for example a Nanobody) comprising:- a CDR1 comprising the amino acid sequence GFTFSSFGMS (SEQ ID NO: 67); e- a CDR2 comprising the amino acid sequence SISGSGSDTL (SEQ ID NO: 68); and- a CDR3 which comprises the amino acid sequence GGSLSR (SEQ ID NO:69); and, optionally, which has:- a degree of sequence identity with the amino acid sequence of SEQ ID NO:66 (wherein any length of C-terminal which may be present, as well as CDRs are not taken into account for determining the degree of sequence identity) of at least 85%, preferably at least 90%, more preferably at least 95% ( where the CDRs, any extension of the C-terminus that may be present, as well as mutations at positions 1, 11, 89, 110 and/or 112 required by the specific aspect involved are not taken into account in determining the degree of identity of sequence); and/or- no more than 7, such as no more than 5, preferably no more than 3, such as only 3, 2 or 1 "amino acid difference" (as defined herein, and not leading to take into account any of the mutations listed above in position (or positions) 1, 11, 89, 110 and/or 112 that may be present. present and not taking into account any C-terminal extension that may be present) with the amino acid sequence of SEQ ID NO: 66 (wherein said amino acid differences, if present, may be present in structures and/or in the CDRs, but are preferably present only in the structures and not in the CDRs); and optionally having:- a C-terminal extension (X)n, where n is 1 to 10, preferably 1 to 5, as 1, 2, 3, 4 or 5 (and preferably 1 or 2 as 1); and each X is an amino acid residue (preferably naturally occurring) that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
[00155] Again, as mentioned, such serum albumin binding ISVD, when present, may contain within its sequence one or more framework mutations that reduce binding by pre-existing antibodies. In particular, when such a serum albumin binding ISVD is a Nanobody or a (single) domain antibody that is, consists essentially of and/or is derived from a VH domain, the serum albumin binding ISVD may contain (a combination suitable de) mutations/amino acid residues at positions 11, 89, 110 and/or 112 which are as described in the document under no. PCT/EP2015/060643 (WO2015/173325) and/or which are essentially as described in this document for the CTLA4 ligands of the invention. For example, document under no. PCT/EP2015/060643 (WO2015/173325) describes various variants of Alb-1, Alb-8 and Alb-23 which contain mutations/amino acid residues at positions 11, 89, 110 and/or 112 which reduce binding by pre-existing antibodies that can be used in the CTLA4 ligands of the invention.
[00156] Again, when such a serum albumin binding ISVD is present at the C-terminal end of a CTLA4 ligand (eg ISVD as a Nanobody) of the invention, the serum albumin binding ISVD (and as a result, the CTLA4 ligand of the invention) preferably has an X(n) C-terminal extension, such C-terminal extension may be as described herein for the CTLA4 ligands of the invention and/or as described in the document under o WO 2012/175741 or PCT/EP2015/060643 (WO2015/173325). It also preferably has mutations that reduce binding of pre-existing antibodies, such as (a suitable combination of) the mutations/amino acid residues at positions 11, 89, 110 and/or 112 described in the document under no. PCT/EP2015 /060643 (WO2015/173325).
[00157] However, as mentioned, other means of increasing the half-life of a CTLA4 ligand of the invention (such as PEGylation, fusion to human albumin or a suitable fragment thereof, or the use of a serum albumin binding peptide suitable), are also included in the scope of the invention.
[00158] In general, when a CTLA4 ligand (e.g., ISVD as a Nanobody) of the invention has increased half-life (e.g. through the presence of a half-life-enhancing ISVD or any other suitable way of increasing the half-life half-life), the resulting CTLA4 ligand preferably has a half-life (as defined herein) which is at least 2 times, preferably at least 5 times, for example at least 10 times or more 20-fold greater than the half-life of the monovalent CTLA4 ligand of the invention (as measured in man and/or in a suitable animal model such as mouse or cynomolgus monkey). In particular, a CTLA4 ligand of the invention preferably has a half-life (as defined herein) in human subjects of at least 1 day, preferably at least 3 days, more preferably at least 7 days , like at least 10 days.
[00159] It will be evident from the disclosure herein that the CTLA4 ligand of the invention (e.g., which is based on one or more ISVDs as Nanobodies) may have different "formats", i.e., be essentially monovalent, bivalent or trivalent, it can be monospecific, bispecific, trispecific, etc., and it can be biparatopic (as defined herein and for example in the document under no. WO 2009/068625). For example, a CTLA4 ligand of the invention can be:
[00160] - (essentially) monovalent, i.e. (essentially) comprising a single CTLA4 binding moiety of the invention. As mentioned, when used in monovalent format, a CTLA4 linker of the invention preferably has a C-terminal X(n) extension as further described herein. Such a CTLA4 ligand of the invention will also have the extended half-life;
[00161] - (essentially) bivalent or trivalent and monospecific. Such a CTLA4 ligand of the invention will comprise two or more chemical binding moieties (e.g., ISVDs) against CTLA4, which may be the same or different and when different may be directed against the same epitope on CTLA4 or against different epitopes on CTLA4 (in the latter case, in order to provide a biparatopic or multiparatopic CTLA4 ligand of the invention). Such a CTLA4 ligand of the invention will also have the extended half-life;
[00162] - (essentially) bivalent, trivalent (or multivalent) ebispecific or trispecific (or multispecific). Such a CTLA4 ligand of the invention will be directed against CTLA4 and at least one other target. As described herein, said other target may be, for example, another therapeutically relevant target (i.e. different from CTLA4), such as, for example, PD1, LAG3, BTLA and/or CD27, in order to provide a binder of CTLA4 that is bispecific with respect to CTLA4 and said other therapeutic target. Said target may also be a target that provides an increased half-life (such as human serum albumin) in order to provide a CTLA4 ligand of the invention that has an increased half-life. As also mentioned herein, such another target may also allow the CTLA4 ligand of the invention to be targeted to specific cells, tissues or organs or may allow the CTLA4 ligand of the invention to be internalized into a cell. It is also possible to combine these approaches/ISVDs, for example, to provide a CTLA4 ligand of the invention that is bispecific for CTLA4 and for at least one other therapeutically relevant target and that has an extended half-life.
[00163] Again, preferably, when such a CTLA4 ligand (e.g., ISVD as a Nanobody) of the invention contains one or more chemical binding moieties (e.g., ISVDs) different from the at least one CTLA4 ligand of the invention, at least minus one and preferably all such other ISVDs will contain within their sequence one or more framework mutations that reduce binding by pre-existing antibodies (such as, in particular, a combination of mutations/amino acid residues at positions 11, 89, 110 and/or 112 which is as described herein for the CTLA4 binders of the invention and/or as described generally in document under no. PCT/EP2015/060643 (WO2015/173325)). Furthermore, when such an inventive CTLA4 ligand has a CTLA4 binding moiety at its C-terminal end, then said C-terminal CTLA4 binding moiety (and as a result, the inventive CTLA4 binding moiety) will have, preferably, a C-terminal X(n) extension as described herein. Similarly, when such a CTLA4 ligand of the invention has another ISVD at its C-terminal end (i.e., not a CTLA4 binding moiety of the invention, but, for example, a half-life extending ISVD), then, said C-terminal ISVD (and as a result, the CTLA4 linker of the invention) will preferably have an X(n) C-terminal extension as described herein and/or will contain within its sequence a or more framework mutations that reduce binding by pre-existing antibodies (again, as further described herein and in document under no. PCT/EP2015/060643 (WO2015/173325)).
[00164] As will be evident to the skilled artisan, when a CTLA4 ligand (e.g., ISVD as a Nanobody) of the invention is intended for topical use (i.e., on the skin or eyes) or is intended, for example, to have a therapeutic action (localized) somewhere, for example, in the GI tract (ie after oral administration or administration by suppository) or in the lungs (ie after administration by inhalation) or is otherwise intended to be applied directly to its intended site of action (eg, by direct injection), a CTLA4 ligand of the invention may not need half-life extension. Furthermore, for the treatment of certain indications or acute conditions, it may be preferable not to have a prolonged half-life. In such cases, the use of a monovalent CTLA4 ligand of the invention or a CTLA4 ligand of the invention (which comprises the CTLA4 binding portion of the invention) without half-life extension (e.g., a CTLA4 ligand of the invention which is bivalent or biparatopic with respect to CTLA4) is preferred.
Some preferred, but non-limiting, examples of such a CTLA4 ligand (eg, ISVD as a Nanobody) of the invention are schematically represented in Table C-1 below, and each of these forms a further aspect of the invention. Other examples of suitable CTLA4 ligands of the invention without a half-life extension will be apparent to the skilled person based on the disclosure herein. half life.


[00166] As will be evident to the skilled artisan, when a CTLA4 ligand (e.g., ISVD as a Nanobody) of the invention is intended for systemic administration and/or prevention and/or treatment of a chronic disorder or disease, it will normally be preferred that said CTLA4 ligand of the invention have an increased half-life (as defined herein). More preferably, such a CTLA4 ligand of the invention will contain a half-life extending ISVD such as, preferably, an ISVD and, in particular, a Nanobody that binds to human serum albumin (as described herein).
[00167] Some preferred, but non-limiting, examples of such CTLA4 ligands (eg, ISVD as a Nanobody) of the invention are schematically represented in Table C-2 below, and each of these forms a further aspect of the invention. Other examples of suitable CTLA4 binder of the invention with extended half-life will be apparent to those skilled in the art based on the disclosure herein. In general, for the half-life extended CTLA4 ligand of the invention, the presence of a C-terminal extension is most preferred. half life



[00168] The present invention also provides a ISVD CTLA4, F023700912 comprising the amino acid sequence: DVQLVESGGGWQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRT YYADSVKGR FTISRDNSKNTVYLQM NSLRPE DTALYYCAA EPSGISGWDYWG QGTLVTV SSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGSEVQLVESGGGWQPGGSLRLS CAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTYYADSVKGRFTISRDNSKNTVY LQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGG GSGGGGSGGGGSGGGGS EVQLVESGGGVVQPGN SLRLSCAASG FTFSS FGMSWVRQA PGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSL SRSSQGTLVTVSSA (SEQ ID NO: 62; 35GS linker underlined with dotted line; CDRs underlined and/or in bold). Optionally, the first residue of any linker moiety in the molecule is replaced with a D or an E as appropriate.
Optionally, the CTLA4 ISVD comprises a signal peptide such as: MRFPSIFTAVLFAASSALAAPTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLEKR (SEQ ID NO:70)
[00170] F023700912 can be encoded by a polynucleotide quecompreende the following nucleotides: gacgtgcaat tggtggagtc tgggggagga gtggtgcagc cggggggctc tctgagactc 60tcctgtgcag cctctggtgg caccttcagt ttctatggca tgggctggtt ccgccaggct 120ccagggaagg agcgcgagtt tgtagcagat attagaacca gtgctggtag gacatactat 180gcagactccg tgaagggccg attcaccatc tccagagaca acagcaagaa cacggtgtat 240ctgcaaatga acagcctgcg ccctgaggac acggccctgt attactgtgc agcagagcca 300agtggaataa gtggttggga ctactggggc caggggaccc tggtcacggt ctcctccgga 360ggcggtgggt caggtggcgg aggcagcggt ggaggaggta gtggcggtgg cggtagtggg 420ggtggaggca gcggaggcgg aggcagtggg ggcggtggat ccgaggtgca gttggtggag 480tctgggggag gagtggtgca gccggggggc tctctgagac tctcctgtgc agcctctggt 540ggcaccttca gtttctatgg catgggctgg ttccgccagg ctccagggaa ggagcgcgag 600tttgtagcag atattagaac cagtgctggt aggacatact atgcagactc cgtgaagggc 660cgattcacca tctccagaga caacagcaag aacacggtgt atctgcaaat gaacagcctg 720cgccctgagg acacggccct gtattactgt gcagcagagc caagtggaat aagtggttgg 780ga ctactggg gccaggggac cctggtcacg gtctcgagcg gaggcggtgg gtcaggtggc 840ggaggcagcg gtggaggagg tagtggcggt ggcggtagtg ggggtggagg cagcggaggc 900ggaggcagtg ggggcggtgg ctcagaggta caactagtgg agtctggagg tggcgttgtg 960caaccgggta acagtctgcg ccttagctgc gcagcgtctg gctttacctt cagctccttt 1020ggcatgagct gggttcgcca ggctccggga aaaggactgg aatgggtttc gtctattagc 1080ggcagtggta gcgatacgct ctacgcggac tccgtgaagg gccgtttcac catctcccgc 1140gataacgcca aaactacact gtatctgcaa atgaatagcc tgcgtcctga agatacggcc 1200 ctgtattact gtactattgg tggctcgtta agccgttctt cacagggtac cctggtcacc 1260gtctcctcag cg 1272(SEQ ID NO: 61; optionally devoid of the signal sequence of nucleotides 1 to 255)
[00171] F023700912 comprises the following portions: • CTLA4 ligand 11F01(E1D,L11V,A14P,Q45R,A74S,K83R,V89L,M96P,Q108L)• 35GS ligand• CTLA4 ligand 11F01(L11 V,A14P,Q45R, A74S,K83R,V89L,M96P,Q108L)• 35GS linker • human serum albumin linker ALB11002; • C-terminal extension alanine. For example: • CTLA4 linker SEQ ID NO: 60 • 35GS linker SEQ ID NO : 65• CTLA4 linker SEQ ID NO: 60 (D1E) • 35GS linker SEQ ID NO: 65• human serum albumin linker SEQ ID NO: 66• Alanine (the present invention includes any linker that includes such an array of portions)
[00172] The present invention also provides a ISVD CTLA4, F023700914 comprising the amino acid sequence: DVQLVESGGGWQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTYYADSVKGR FTISRDNSKNTVYLQM NSLRPE DTALYYCAA EPSGISGWDYWG QGTLVTV SSGGGGSGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVQPGNSLRL SCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLY LQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSA (SEQ ID NO: 64; linker 35GS underlined with dotted line; CDRs underlined and / or in bold). Optionally, the first residue of any linker moiety in the molecule is replaced with a D or an E as appropriate.
Optionally, the CTLA4 ISVD comprises a signal peptide such as: MRFPSIFTAVLFAASSALAAPTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLL FINTTIASIAAKEEGVSLEKR (SEQ ID NO:70)
[00174] F023700914 can be encoded by a polynucleotide quecompreende the following nucleotides: gacgtgcaat tggtggagtc tgggggagga gtggtgcagc cggggggctc tctgagactc 60 tcctgtgcag cctctggtgg caccttcagt ttctatggca tgggctggtt ccgccaggct 120ccagggaagg agcgcgagtt tgtagcagat attagaacca gtgctggtag gacatactat 180gcagactccg tgaagggccg attcaccatc tccagagaca acagcaagaa cacggtgtat 240ctgcaaatga acagcctgcg ccctgaggac acggccctgt attactgtgc agcagagcca 300agtggaataa gtggttggga ctactggggc caggggaccc tggtcacggt ctcctccgga 360ggcggtgggt caggtggcgg aggcagcggt ggaggaggta gtggcggtgg cggtagtggg 420ggtggaggca gcggaggcgg aggcagtggg ggcggtggat ccgaggtgca gttggtggag 480tctggaggtg gcgttgtgca accgggtaac agtctgcgcc ttagctgcgc agcgtctggc 540tttaccttca gctcctttgg catgagctgg gttcgccagg ctccgggaaa aggactggaa 600tgggtttcgt ctattagcgg cagtggtagc gatacgctct acgcggactc cgtgaagggc 660cgtttcacca tctcccgcga taacgccaaa actacactgt atctgcaaat gaatagcctg 720cgtcctgaag atacggccct gtattactgt actattggtg gctcgttaag 780c ccgttcttca agggtaccc tggtcaccgt ctcctcagcg 810(SEQ ID NO: 63; optionally devoid of the signal sequence of nucleotides 1 to 255)
[00175] F023700912 comprises the following portions: • CTLA4 ligand 11F01 (E1D,L11V,A14P,Q45R,A74S,K83R,V89L,M96P,Q108L);• 35GS ligand;• human serum albumin ligand ALB11002;• alanine from C-terminal extension. For example: • CTLA4 linker SEQ ID NO: 60 • 35GS linker SEQ ID NO: 65 • human serum albumin linker SEQ ID NO: 66 • Alanine (the present invention includes any linker that includes such an arrangement of portions)
The present invention includes any multispecific CTLA4 linker that comprises the amino acid sequence of SEQ ID NO: 62 or 64 or an amino acid sequence that comprises 80% or more (e.g. 85%, 90%, 95%, 96%, 97%, 98% or 99%) amino acid sequence identity, wherein the CTLA4 linker retains the ability to bind CTLA4 and, optionally, HSA. Cross Blocking and Epitope Linking
The present invention provides CTLA4 ligands disclosed herein (for example, F023700912 or F023700914) as well as linkers, for example, comprising CTLA4 ISVDs (for example, Nanobodies) that bind to the same CTLA4 epitope as such binders. For example, the present invention includes ligands that bind to human CTLA4 by contacting the same residues as F023700912 or F023700914. For example, the present invention provides linkers that bind to human CTLA4 at residues VRVTVL (residues 33 to 38 of SEQ ID NO: 110), ADSQVTEVC (residues 41 to 49 of SEQ ID NO: 110) and/or CKVELMYPPPYYLG (residues 93 to 106 of SEQ ID NO: 110), for example, all three sites, of human CTLA4. In one embodiment of the invention, the ligand demonstrates binding to human CTLA4 on these residues in a hydrogen-deuterium exchange assay, for example, protects the residues against deuterium-hydrogen exchange in the presence of deuterium such as D2O, for example, as depicted by a binding heat map, essentially as shown in Figure 13.
The present invention includes a CTLA4 linker (for example, F023700912 or F023700914 or 11F01 or any of their variants shown herein) which is linked to a polypeptide comprising the VRVTVL peptide sequences (residues 33 to 38 of SEQ ID NO: 110), ADSQVTEVC (residues 41 to 49 of SEQ ID NO: 110) and/or CKVELMYPPPYYLG (residues 93 to 106 of SEQ ID NO: 110), for example CTLA4. Optionally, the polypeptide is on the surface of a cell, e.g., a T cell, and the polypeptide is bound by the CTLA4 linker.
[00179] The present invention also provides cross-blocking binders that have the ability to cross-block the binding of any of the binders described herein (for example, F023700912 or F023700914). Such cross-blocking ligands can be any molecule that exhibits such cross-blocking, for example, an ISVD, Nanobody, antibody or antigen-binding fragment thereof.
[00180] In general, a linker (eg ISVD as Nanobody) or antibody or antigen-binding fragment thereof that "cross-blocks" a reference linker refers to a linker (eg ISVD as Nanobody) or antibody or antigen-binding fragment thereof that blocks the binding of the reference ligand to its antigen in a competition assay by 50% or more, and on the other hand, the reference ligand blocks binding of the ligand (eg, ISVD as Nanobody) or antibody or antigen-binding fragment thereof to its antigen in a competition assay by 50% or greater. Cross-blocking can be determined in any assay known in the art, including surface plasmon resonance (SPR), ELISA and flow cytometry.
[00181] In one embodiment of the invention, cross-blocking is determined using a Biacore assay. For convenience, reference is made to two ligands, however, the scope of the present invention includes antibodies and antigen-binding fragments thereof, e.g. Fab fragments, which cross-block a ligand of the present invention. A Biacore machine (eg the Biacore 3000) is operated in line with the manufacturer's recommendations.
[00182] Thus, in a cross-blocking assay, CTLA4 is coupled to a CM5 Biacore chip using standard amine coupling chemistry to generate a surface coated with CTLA4. For example, 200 to 800 CTLA4 resonance units would be coupled to the chip (or any amount that generates easily measurable levels of binding but is readily saturable by the concentrations of test reagent that is used). The two ligands (called A* and B*) to be evaluated for their ability to cross-block each other are mixed in a one-to-one (1:1) molar ratio of binding sites in a buffer suitable for create the test mix.
[00183] The concentration of each ligand in the test mixture should be high enough to readily saturate the binding sites for that ligand on the CTLA4 molecules captured on the Biacore chip. The binders in the mixture are at the same molar concentration.
Separate solutions containing linker A* alone and linker B* alone are also prepared. Binding A* and Binding B* in these solutions should be in the same buffer and at the same concentration as in the test mixture.
[00185] The test mixture is passed over the CTLA4 coated Biacore chip and the total amount of binding is recorded. The chip is then treated in such a way in order to remove the bound ligands without damaging the CTLA4 bound to the chip. In one embodiment of the invention, this is done by treating the chip with 30 mM HCl for 60 seconds.
[00186] The A* binder solution alone is then passed over the CTLA4 coated surface and the amount of binding is recorded. The chip is again treated to remove all bound ligand without damaging the CTLA4 attached to the chip.
[00187] The B* binder solution alone is then passed over the CTLA4 coated surface and the amount of binding is recorded.
[00188] The theoretical maximum binding of the mixture of binder A* and binder B* is then calculated and is the sum of the binding of each binder when passed over the CTLA4 surface alone. If the actual recorded binding of the mixture is less than this theoretical maximum, then the two binders are cross-blocking each other.
[00189] Thus, in general, a cross-blocking ligand according to the invention is one that will bind CTLA4 in the Biacore cross-blocking assay above, so that, during the assay and in the presence of a second ligand, the binding recorded is between, for example, 80% and 0.1% (eg 80% to 4%>) of the maximum theoretical binding, for example, between 75% and 0.1%> (eg 75% at 4%>) of the maximum theoretical binding, eg between 70% and 0.1% (eg 70% to 4%) of the maximum theoretical binding (as already defined above) of the two binders in combination.
[00190] In one embodiment of the invention, an ELISA assay is used to determine whether a CTLA4 ligand cross-blocks or has the ability to cross-block in accordance with the invention.
[00191] The general principle of the assay is to have a CTLA4 ligand coated on the wells of an ELISA plate. An excess amount of a second potentially cross-blocking CTLA4 ligand is added in solution (i.e., not bound to the ELISA plate). A limited amount of CTLA4 is then added to the wells. The coated ligand and the ligand in solution compete to bind the limited number of CTLA4 molecules. The plate is washed to remove CTLA4 that has not been bound by the coated binder and to also remove the second solution phase binder as well as any complexes formed between the second solution phase binder and CTLA4. The amount of CTLA4 bound is then measured using an appropriate CTLA4 detection reagent. A ligand in solution that has the ability to cross-block the coated ligand will be able to cause a decrease in the number of CTLA4 molecules that the coated ligand can bind, relative to the number of CTLA4 molecules that the coated ligand can bind in the absence of the second solution phase binder. expression methods
[00192] The present invention includes recombinant methods for making a CTLA4 linker (for example an ISVD as a Nanobody) of the present invention (for example F023700912 or F023700914) which comprises (i) introducing a polynucleotide encoding the amino acid sequence of said CTLA4 linker, for example, wherein the polynucleotide is in a vector and/or is operably linked to a promoter; (ii) culturing the host cell (e.g., CHO or Pichia or Pichia pastoris) under a favorable condition for the expression of the polynucleotide and, (iii) optionally, isolating the CTLA4 ligand from the host cell and/or medium in which the host cell is cultured. See, for example, WO 04/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or WO 2009/068627.
The invention also relates to polynucleotides encoding CTLA4 binders of the present invention (for example an ISVD such as a Nanobody) as described herein (for example F023700912 or F023700914). Polynucleotides can be, in one embodiment of the invention, operably linked to one or more control sequences. The polynucleotide can be in the form of a plasmid or vector. Again, such polynucleotides may generally be as described in published Ablynx NV patent applications such as, for example, WO 04/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or WO 2009/068627 .
The invention also relates to hosts or host cells that contain such CTLA4 polynucleotides, vectors and/or ligands described herein (for example, F023700912 or F023700914). Again, such host cells may generally be as described in published Ablynx NV patent applications such as, for example, WO 04/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or WO 2009/ 068627. Examples of specific host cells are discussed below.
[00195] Eukaryotic and prokaryotic host cells, including mammalian cells, as hosts for the expression of the CTLA4 ligand (eg, ISVD as a Nanobody) are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC). These include but are not limited to Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, newborn hamster kidney (BHK) cells, monkey kidney (COS) cells, human hepatocellular carcinoma cells (by example, Hep G2), A549 cells, 3T3 cells, HEK-293 cells, and several other cell lines. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, bovine, horse and hamster cells. Particularly preferred cell lines are selected by determining which cell lines have high expression levels. Other cell lines that can be used are insect cell lines (eg Spodoptera frugiperda or Trichoplusia ni), amphibian cells, bacterial cells, plant cells and fungal cells. Fungal cells include yeast and filamentous fungus cells including, for example, Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia salictaria, guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces sp., Hansenula polymorpha, Kluyveromyces sp. Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens and Neurospora crassa. Pichia sp., any Saccharomyces sp., Hansenula polymorpha, any Kluyveromyces sp., Candida albicans, any Aspergillus sp., Trichoderma reesei, Chrysosporium lucknowense, my Fusarium sp., Yarrowia lipolytica and Neurospora crassa. The present invention includes any host cell (e.g., a CHO cell or Pichia cell, e.g., Pichia pastoris) that contains a CTLA4 linker of the present invention (e.g., F023700912 or F023700914) or that contains a polynucleotide encoding such a linker or that contains a vector that contains the polynucleotide.
[00196] Additionally, the expression of a CTLA4 ligand (eg an ISVD such as a Nanobody) from production cell lines can be enhanced using various known techniques. For example, the glutamine synthetase gene expression system (the GS system) is a common approach to enhance expression under certain conditions. The GS system is discussed in whole or in part in conjunction with European Patent Nos. 0 216 846, 0 256 055 and 0 323 997 and European Patent Application No. 89303964.4. Thus, in one embodiment of the invention, mammalian host cells (eg, CHO) are devoid of a glutamine synthetase gene and are cultured in the absence of glutamine in the medium in which, however, the polynucleotide encoding the chain of Immunoglobulin comprises a glutamine synthetase gene that complements the lack of the gene in the host cell. Such host cells that contain the linker, polynucleotide or vector as discussed herein, as well as expression methods, as discussed herein, for making the linker using such a host cell are part of the present invention.
[00197] The present invention includes methods for purifying a CTLA4 ligand (e.g., ISVD as a Nanobody) which comprises introducing a sample (e.g., culture medium, cell lysate or cell lysate fraction, e.g., a soluble fraction of the lysate) comprising the CTLA4 ligand to a purification medium (eg, cation exchange media, anion exchange media, hydrophobic exchange media, affinity purification media (eg, protein A, protein G, protein A /G, protein L)) and collecting purified CTLA4 ligand from the through-flow fraction of said sample that does not bind to the medium; or, discharge the flow-through fraction and elute the bound CTLA4 ligand from the medium and collect the eluate. In one embodiment of the invention, the medium is in a column to which the sample is applied. In one embodiment of the invention, the purification method is conducted after recombinant expression of the antibody or fragment in a host cell, for example, where the host cell is first lysed and, optionally, the lysate is purified from insoluble materials prior to purification. in a medium; or wherein the CTLA4 ligand is secreted into the culture medium by the host cell and the medium or a fraction thereof is applied to the purification medium.
[00198] In general, glycoproteins produced in a particular transgenic animal or cell line will have a glycosylation pattern that is characteristic for glycoproteins produced in the transgenic animal or cell line. Therefore, the particular glycosylation pattern of a CTLA4 ligand (eg, ISVD as a Nanobody) will depend on the particular cell line or transgenic animal used to produce the CTLA4 ligand. CTLA4 ligands comprising only non-fucosylated N-glycans are part of the present invention and may be advantageous due to the fact that non-fucosylated antibodies have been shown to exhibit more potent efficacy than their fucosylated counterparts both in vitro and in vivo (See , for example, Shinkawa et al., J. Biol. Chem. 278: 3,466 to 3,473 (2003); US patents 6,946,292 and 7,214,775). These CTLA4 ligands with non-fucosylated N-glycans are not likely to be immunogenic due to the fact that their carbohydrate structures are a normal component of the population that exists in human serum IgG.
The present invention includes CTLA4 linkers comprising N-linked glycans that are typically added to immunoglobulins produced in Chinese hamster ovary cells (CHO N-linked glycans) or to modified yeast cells (N-linked glycans of modified yeast), such as Pichia pastoris. For example, in one embodiment of the invention, the CTLA4 ligand (e.g., ISVD as a Nanobody) comprises one or more of the "modified yeast N-linked glycans" or "CHO N-linked glycans" which are set forth in Figure 4 (for example, G0 and/or G0-F and/or G1 and/or G1-F and/or and/or G2-F and/or Man5). In one embodiment of the invention, the CTLA4 linker comprises the modified yeast N-linked glycans, i.e., G0 and/or G1 and/or G2, optionally, which further include Man5. In one embodiment of the invention, the CTLA4 linkers comprise the N-linked glycans of CHO, i.e., G0-F, G1-F and G2-F, optionally, which further include G0 and/or G1 and/or G2 and/or Man5. In one embodiment of the invention, about 80% to about 95% (e.g., about 80 to 90%, about 85%, about 90% or about 95%) of all N-linked glycans in the linkers of CTLA4 are modified yeast N-linked glycans or CHO N-linked glycans. See Nett et al. Yeast. 28(3): 237 to 252 (2011); Hamilton et al. Science. 313(5792): 1,441 to 1,443 (2006); Hamilton et al. Curr Opin Biotechnol. 18(5): 387 to 392 (2007). For example, in one embodiment of the invention, a genetically modified yeast cell is GFI5.0 or YGLY8316 or strains disclosed in U.S. Patent No. 7,795,002 or Zha et al. Methods Mol Biol. 988:31 to 43 (2013). See also International Patent Application Publication No. WO2013/066765. combinations
[00200] In particular embodiments, the CTLA4 ligands (e.g., ISVD as a Nanobody) of the present invention can be used alone or in association with other therapeutic agents and/or additional therapeutic procedures, to treat or prevent any disease such as cancer, for example, as discussed herein, in an individual in need of such treatment or prevention. Compositions or kits, for example pharmaceutical compositions which comprise a pharmaceutically acceptable carrier, which comprise such CTLA4 binders in association with additional therapeutic agents are also part of the present invention.
The term "in association with" indicates that the components, a CTLA4 ligand (e.g., ISVD as a Nanobody) of the present invention together with another agent such as pembrolizumab or nivolumab, can be formulated into a single composition, by for example, for simultaneous delivery, or formulated separately into two or more compositions (eg, a kit). Each component can be administered to an individual at a different time than when the other component is administered; for example, each administration may be given non-simultaneously (eg, separately or sequentially) at intervals over a given period of time. Furthermore, the separate components can be administered to an individual via the same route or a different route (for example, where a CTLA4 ligand of the present invention is administered parenterally and paclitaxel is administered orally).
In particular embodiments, CTLA4 ligands (e.g., ISVD as a Nanobody) can be used in combination with an anti-cancer therapeutic agent or immunomodulatory drug such as an immunomodulatory receptor inhibitor, e.g., an antibody or fragment of binding to the same antigen that specifically binds to the receptor.
[00203] In one embodiment of the invention, a CTLA4 ligand (eg, ISVD as a Nanobody) is in association with one or more of inhibitors (eg, a small organic molecule or an antibody or antigen-binding fragment thereof ) as: an MTOR (mammalian target of rapamycin) inhibitor, a cytotoxic agent, a platinum agent, a BRAF inhibitor, a CDK4/6 inhibitor, an EGFR inhibitor, a VEGF inhibitor, a microtubule stabilizer , a taxane, an inhibitor of CD20, an inhibitor of CD52, an inhibitor of CD30, an inhibitor of RANK (activator of nuclear factor kappa-B receptor), an inhibitor of RANKL (activator of nuclear factor receptor kappa- B), an ERK inhibitor, a MAP kinase inhibitor, an AKT inhibitor, a MEK inhibitor, a PI3K inhibitor, an inhibitor of HER1, an inhibitor of HER2, an inhibitor of HER3, an inhibitor of HER4, a Bcl2 inhibitor, a CD22 inhibitor, a CD79b inhibitor, an ErbB2 inhibitor, or a protein inhibitor. farnesyl transferase.
In one embodiment of the invention, a CTLA4 ligand (eg, ISVD as a Nanobody) is in association with one or more of: anti-CTLA4 antibodies or antigen-binding fragments thereof (eg, ipilimumab), anti-PD1 antibody or antigen-binding fragment thereof (eg pembrolizumab, nivolumab, CT-011), anti-PDL1, anti-CTLA4, anti-TIM3, anti-CS1, (eg elotuzumab), anti- KIR2DL1/2/3 (eg lirilumab), anti-CD27, anti-CD137 (eg urelumab), anti-GITR (eg TRX518), anti-PD-L1 (eg BMS-936559, MSB0010718C or MPDL3280A), anti-PD-L2, anti-ILT1, anti-ILT2, anti-ILT3, anti-ILT4, anti-ILT5, anti-ILT6, anti-ILT7, anti-ILT8, anti-CD40, anti-OX40, anti-CD 137, anti-KIR2DL1, anti-KIR2DL2/3, anti-KIR2DL4, anti-KIR2DL5A, anti-KIR2DL5B, anti-KIR3DL1, anti-KIR3DL2, anti-KIR3DL3, anti-NKG2A, anti-NKG2C, anti-KG2E , or any small organic molecule inhibitor of such targets; IL-10, anti-IL10, anti-TSLP (thymic stromal lymphopoietin) or PEGylated IL-10.
[00205] In one embodiment of the invention, the molecular weight of the polyethylene glycol (PEG) moiety in a PEGylated IL-10 molecule is about 12,000 daltons or about 20,000 daltons. In one embodiment of the invention, PEGylated IL-10 (e.g., PEGylated human IL-10) comprises one or more polyethylene glycol molecules covalently attached through a linker (e.g., C2-12 alkyl such as—CH2CH2CH2—) to a single amino acid residue of a single IL-10 subunit, wherein said amino acid residue is the alpha amino group of the N-terminal amino acid residue or the epsilon amino group of a lysine residue. In one embodiment of the invention, PEGylated IL-10 is: (PEG)b-L-NH-IL-10; where b is 1 to 9 and L is a C2-12 alkyl linker moiety covalently attached to a nitrogen (N) of the single amino acid residue of IL-10. In one embodiment of the invention, the PEGylated IL-10 IL-10 has the Formula: [X-O(CH2CH2O)n]b-L-H-IL-10, wherein X is H or C1-4 alkyl; n is 20 to 2300; b is 1 to 9; and L is a linker moiety of C1-11 that is covalently attached to the nitrogen (N) of the alpha amino group at the amino terminus of an IL-10 subunit; provided that when b is greater than 1, the total of n does not exceed 2300. See document US7.052,686.
In one embodiment of the invention, the anti-IL-10 antibody or antigen-binding fragment thereof (e.g., humanized antibody) comprises the CDRs shown below:CDR-L1: KTSQNIFENLA (SEQ ID NO: 71); CDR-L2: NASPLQA (SEQ ID NO:72);CDR-L3: HQYYSGYT (SEQ ID NO:73);CDR-H1:GFTFSDYHMA (SEQ ID NO:74);CDR-H2:SITLDATYYRDSVRG (SEQ ID NO:75) );CDR-H3: HRGFSVWLDY (SEQ ID NO: 76); (See US7.662,379)
In one embodiment of the invention, the anti-TSLP antibody or antigen-binding fragment thereof (e.g., humanized antibody) comprises the CDRs shown below:CDR-H1: GYIFTDYAMH (SEQ ID NO: 77);CDR- H2: TFIPLLDTSDYNQNFK (SEQ ID NO: 78); CDR-H3: MGVTHSYVMDA (SEQ ID NO: 79); CDR-L1: RASQPISISVH (SEQ ID NO: 80);CDR-L2: FASQSIS (SEQ ID NO: 81);CDR-L3: QQTFSLPYT (SEQ ID NO: 82); );(see WO2008/76321)
In one embodiment of the invention, the anti-CD27 antibody or antigen-binding fragment thereof (e.g., humanized antibody) comprises the CDRs shown below:CDR-H1: GFIIKATYMH (SEQ ID NO:83);CDR- H2: RIDPANGETKYDPKFQV (SEQ ID NO: 84);CDR-H3: YAWYFDV (SEQ ID NO: 85);CDR-L1: RASENIYSFLA (SEQ ID NO: 86);CDR-L2: HAKTLAE (SEQ ID NO: 87) ;CDR-L3: QHYYGSPLT (SEQ ID NO: 88); (see WO2012/04367).
Thus, the present invention includes compositions comprising a CTLA4 ligand (e.g., ISVD as a Nanobody) in association with pembrolizumab; as well as methods of treating or preventing cancer in a subject which comprises administering an effective amount of the CTLA4 ligand in combination with pembrolizumab (e.g. pembrolizumab dosed at 200 mg once every three weeks) to the subject. Optionally, another additional therapeutic agent in combination is also administered to the individual.
In one embodiment of the invention, a CTLA4 binder (eg ISVD as a Nanobody) is in association with a pembrolizumab antibody comprising an immunoglobulin heavy chain (or CDR-H1, CDR-H2 and CDR-H3 of the thereof) comprising the amino acid sequence: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNG GTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSWTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGG PSVFLFPPKPKDTLMISRTPEVTCVWDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTYRWSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR WQEGNVFSCSVMHEALHNHYTQKSLSLSLGK; (SEQ ID NO: 89), and an immunoglobulin light chain (or CDR-L1, CDR-L2 and CDR-L3 thereof) comprising the amino acid sequence: EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGV PARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90).
In one embodiment of the invention, a CTLA4 binder (eg, ISVD as a Nanobody) is in association with an antibody comprising an immunoglobulin heavy chain (or CDR-H1, CDR-H2 and CDR-H3 thereof ) comprising the amino acid sequence: QVQLVESGGGWQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSK RYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSWTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPK PKDTLMISRTPEVTCVWDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRWSVL TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS VMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 91) and a light immunoglobulin chain (or CDR-L1, CDR-L2 and CDR-L3 thereof) comprising the sequence amino acids:EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARF SGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQ LKSGTASWCLLNNFYPREAKVQSGWDN QESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 92).
[00212] In one embodiment of the invention, a CTLA4 ligand is in association with any one or more of: 13-cis-retinoic acid, 3-[5-(methylsulfonylpiperadinmethyl)-indolyl]-quinolone, 4-hydroxytamoxifen, 5- deoxyuridine, 5'-deoxy-5-fluorouridine, 5-fluorouracil, 6-mecaptopurine, 7-hydroxystaurosporine, A-443654, abiraterone acetate, abraxane, ABT-578, acolbifen, ADS-100380, aflibercept, ALT-110, altretamine , amifostine, aminoglutethimide, anrubicin, ansacrine, anagrelide, anastrozole, angiostatin, AP-23573, ARQ-197, arzoxifene, AS-252424, AS-605240, asparaginase, ATI3387, AT-9263, atrasentan, axitinib, AZD1152 vaccine Calmette-Guérin (BCG), batabulin, BC-210, besodutox, bevacizumab, BGJ398, bicalutamide, Biol 11, BIO140, BKM120, bleomycin, BMS-214662, BMS-247550, BMS-275291, BMS-310705, bortezimib, buserelin busulfan, calcitriol, camptothecin, canertinib, capecitabine, carboplatin, carmustine, CC8490, CEA (vaccinia recombinant-an vaccine) carcinoembryonic antigen), cediranib, CG-1521, CG-781, clamidocine, chlorambucil, chlorotoxin, cilengitide, cimitidine, cisplatin, cladribine, clodronate, cobimetnib, COL-3, CP-724714, cyclophosphamide, cyproterone, cyproterone acetate, cytarabine, cytosine-arabinoside, dabrafenib, dacarbazine, dacinostat, dactinomycin, dalotuzumab, danusertib, dasatanib, daunorubicin, decatanib, deguelin, denileucine, deoxycoformycin, depsipeptide, diarylpropionitrile, diethylstylbethrone, dotoxy, diethylstilbestrol, diethylstylbestrol, with yttrium-90, edotreotide, EKB-569, EMD121974, encorafenib, endostatin, enzalutamide, enzastaurin, epirubicin, epitilone B, ERA-923, erbitux, erlotinib, estradiol, estramustine, etoposide, everolimus, phycolate, exemestane floxuridine, fludarabine, fludrocortisone, fluoxymesterone, flutamide, FOLFOX regimen, fulvestrant, galeterone, ganetespib, gefitinib, gencitabin a, gimatecan, glucopyranosyl lipid A, goserelin, goserelin acetate, gossypol, GSK461364, GSK690693, HMR-3339, hydroxyprogesterone caproate, hydroxyurea, IC87114, idarubicin, idoxifene, ifosfamide, IM862, imadectinib, INCB24360, INO1001, interferon, interleukin-2, interleukin-12,ipilimumab, irinotecan, JNJ-16241199, ketoconazole, KRX-0402, lapatinib, lasofoxifene, LEE011, letrozole, leucovorin, leuprolide, leuprolide acetate, levamisole liposome, pac , lomustine, telafarnib, lucantone, LY292223, LY292696, LY293646, LY293684, LY294002, LY317615, LY3009120, marimastat, mechlorethamine, medroxyprogesterone acetate, megestrol acetate, MEK162, melphalan, mitothromycin, mitotrenomycin , a suspension of heat-killed Mycobacterium obuense, tozasertib, MLN8054, natitoclax, neovastat, Neratinib, neuradiab, nilotinib, nilutimid, nolatrexed, NVP-BEZ235, oblime rsen, octreotide, ofatumumab, oregovomab, ornatuzumab, orteronel, oxaliplatin, paclitaxel, palbociclib, pamidronate, panitumumab, pazopanib, PD0325901, PD184352 75, pipendoxifen, PKI-166, plicamycin, poly-ICLC, porfimer, prednisone, procarbazine, progestins, polysaccharide linked to PSK protein (derived from Basidiomycete coriolus versicolor), PLX8394, PX-866, R-763, raloxifene, raltioxitrexede, raz , ridaforolimus, rituximab, romidepsin, RTA744, rubitecan, scriptaid, Sdx102, seliciclib, selumetinib, semaxanib, SF1126, sirolimus, SN36093, sorafenib, spironolactone, squalamine, SRI 3668, synthetic streptozomic acid streptozocin, SU66 , talimogene laherparepvec, tamoxifen, temozolomide, temsirolimus, teniposide, tesmilifene, testosterone, tetrandrine, TGX-221, thalidomide, 6-thioguanine, thiotepa, ticilimumab, tipifarnib, tivozanib, TKI-258, TLK286, TNF-α (tumor necrosis factor alpha), topotecan, toremifene citrate, trabectedin, trametinib, trastuzumab, tretinoin, trichostatin A, triciribin phosphate monohydrate, triptorelin pamoate, TSE-424 , uracil mustard, valproic acid, valrubicin, vandetanib, vatalanib, VEGF trap, vemurafenib, vinblastine, vincristine, vindesine, vinorelbine, vitaxin, vitespan, vorinostat, VX-745, wortmanin, Bacillus Xr311 hot water extract tuberculosis, zanolimumab, ZK186619, ZK-304709, ZM336372 or ZSTK474.
[00213] In one embodiment of the invention, a CTLA4 ligand (eg, ISVD as a Nanobody) is in association with one or more antiemetics which include, but are not limited to: casopitant (GlaxoSmithKline), Netupitant (MGI-Helsinn) and others NK-1 receptor antagonists, palonosetron (sold as Aloxi by MGI Pharma), aprepitant (sold as Emend by Merck and Co.; Rahway, NJ), diphenhydramine (sold as Benadryl® by Pfizer; New York, NY), hydroxyzine (sold as Atarax® by Pfizer; New York, NY), metoclopramide (sold as Reglan® by AH Robins Co.; Richmond, VA), lorazepam (sold as Ativan® by Wyeth; Madison, NJ), alprazolam (sold as Xanax ® by Pfizer; New York, NY), halopendol (sold as Haldol® by Ortho-McNeil; Raritan, NJ), droperidol (Inapsine®), dronabinol (sold as Marinol® by Solvay Pharmaceuticals, Inc.; Marietta, GA), dexamethasone (sold as Decadron® by Merck and Co.; Rahway, NJ), methylprednisolone (sold as Medrol® by Pfizer; N New York, NY), prochlorperazine (sold as Compazine® by Glaxosmithkline; Research Triangle Park, NC), granissetron (sold as Kytril® by Hoffmann-La Roche Inc.; Nutley, NJ), ondansetron (sold as Zofran® by Glaxosmithkline; Research Triangle Park, NC), dolassetron (sold as Anzemet® by Sanofi - Aventis; New York, NY), tropissetron (sold as Navoban® by Novartis; East Hanover, NJ).
[00214] Other side effects of cancer treatments include red blood cell and white blood cell deficiency. Accordingly, in one embodiment of the invention, a CTLA4 ligand (eg, ISVD as a Nanobody) is in association with an agent that treats or prevents such a deficiency, such as, for example, filgrastim, PEG-filgrastim, erythropoietin, epoetin alfa or darbepoetin alfa.
In one embodiment of the invention, a CTLA4 ligand (eg ISVD as a Nanobody) is in association with a vaccine. In one embodiment of the invention, the vaccine is an anti-cancer vaccine, a peptide vaccine or a DNA vaccine. For example, in one embodiment of the invention, the vaccine is a tumor cell (eg, an irradiated tumor cell) or a dendritic cell (eg, a dendritic cell pulsed with a tumor peptide).
In one embodiment of the invention, a CTLA4 ligand (eg, ISVD as a Nanobody) is administered in association with a therapeutic procedure. A therapeutic procedure is one or more steps performed by a physician or clinician in the treatment of an individual that is intended to alleviate one or more symptoms (eg, of cancer and/or infectious disease) in the treated individual, if through induction of regression or elimination of such symptoms or by inhibiting the progression of such symptom (or symptoms), for example cancer symptoms such as tumor growth or metastasis, to any clinically measurable degree.
[00217] In one embodiment of the invention, a therapeutic procedure is anti-cancer radiation therapy. For example, in one embodiment of the invention, the radiotherapy is external beam therapy (EBT): a method of delivering a high-energy X-ray beam to the tumor site. The beam is generated outside the patient (eg by a linear accelerator) and is directed at the tumor site. These X-rays can destroy cancer cells and careful treatment planning allows the surrounding normal tissues to be spared. No radioactive sources are placed inside the patient's body. In one embodiment of the invention, radiation therapy is proton beam therapy: a type of conformal therapy that bombards diseased tissue with protons instead of X-rays. In one embodiment of the invention, radiation therapy is conformal external beam radiation therapy: a procedure that uses advanced technology to adapt radiotherapy to an individual's bodily structures.
[00218] In one embodiment of the invention, radiotherapy is brachytherapy: the temporary placement of radioactive materials within the body, normally used to generate an extra dose — or boost — of radiation to an area.
[00219] In one embodiment of the invention, a surgical procedure administered in association with a CTLA4 ligand (eg, ISVD as a Nanobody) is surgical lumpectomy. therapeutic uses
The invention includes a method for the prevention and/or treatment of at least one disease or disorder that can be prevented or treated with the use of a CTLA4 ligand (e.g., ISVD as a Nanobody) of the present invention, optionally in association with an additional therapeutic agent or therapeutic procedure, such method comprises administering to a subject in need of such treatment a pharmaceutically active amount of the CTLA4 ligand and/or a pharmaceutical composition comprising the same.
"Treating" or "treatment" means administering a CTLA4 ligand (eg, ISVD as a Nanobody) of the present invention, to an individual (eg, a mammal such as a human) who has one or more symptoms of a disease for which CTLA4 ligands are effective, for example, in the treatment of an individual who has cancer or an infectious disease, or who is suspected of having cancer or an infectious disease, for which the agent has therapeutic activity. Typically, CTLA4 ligand is administered in an "effective amount" or "effective dose" that will alleviate one or more symptoms (eg, of cancer or infectious disease) in the treated individual or population, whether through induction of regression or eliminating such symptoms or by inhibiting the progression of such symptom (or symptoms), for example cancer symptoms such as tumor growth or metastasis, to any clinically measurable degree. The effective amount of CTLA4 ligand can vary depending on factors such as the stage of the disease, age and weight of the patient, and the ability of the drug to elicit a desired response in the individual.
[00222] The subject to be treated may be any warm-blooded animal, but is in particular a mammal, and more particularly a human being. As will be apparent to the person skilled in the art, the individual to be treated will, in particular, be a person suffering from, or at risk of, the diseases and disorders mentioned herein. In general, the treatment regimen will be followed until the desired therapeutic effect is achieved and/or while the desired therapeutic effect is to be maintained. Again, this can be determined by the clinician.
[00223] CTLA4 ligands (eg ISVD as a Nanobody), polypeptides, compounds and polynucleotides (eg vectors) described herein are preferably administered into the circulation. As such, they can be administered in any suitable manner that allows CTLA4 ligands, polypeptides, compounds and polynucleotides to enter the circulation, such as intravenously, via injection or infusion, or in any other suitable manner (which includes oral administration, subcutaneous administration, intramuscular administration, administration through the skin, intranasal administration, administration through the lungs, etc.) which allows CTLA4 ligands, polypeptides, compounds and polynucleotides to enter the circulation. Suitable methods and routes of administration will be apparent to the person skilled in the art, again, for example, also from the teaching of published patent applications of Ablynx NV, such as, for example, WO 04/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or WO 2009/068627.
[00224] To prepare pharmaceutical or sterile compositions of the CTLA4 binders (eg, ISVD as a Nanobody) of the present invention, the CTLA4 binders are mixed by addition with a pharmaceutically acceptable excipient or carrier. See, for example, Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984) or Remington's Pharmaceutical Sciences. Such compositions form part of the present invention.
[00225] The scope of the present invention includes desiccated, e.g., lyophilized, compositions which comprise CTLA4 binders (e.g. ISVD as a Nanobody) or a pharmaceutical composition thereof which includes a pharmaceutically acceptable carrier but is substantially devoid of water .
[00226] The formulations of diagnostic and therapeutic agents may be prepared by mixing with acceptable carriers, excipients or stabilizers in the form of, for example, lyophilized powders, slurries, aqueous suspensions or solutions (see, for example, Hardman , et al (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al.(eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al.(eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al.(eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; al.(eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY; Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY).
[00227] In general, for the prevention and/or treatment of the diseases or disorders mentioned herein and depending on the specific disorder or disease to be treated, the potency and/or the half-life of the constructs or fusion proteins to be used , the specific route of administration and the specific pharmaceutical formulation or composition used, the Nanobodies and polypeptides of the invention will, in general, be administered in an amount between 1 gram and 0.01 microgram per kg of body weight per day, preferably between 0.1 gram and 0.1 microgram per kg of body weight per day, such as about 1, 10, 100 or 1,000 micrograms per kg of body weight per day, either continuously (eg by infusion) as a daily dose single or multiple divided doses during the day. The clinician, in general, will be able to determine an adequate daily dose, depending on the factors mentioned in this document. It will also be evident that in specific cases, the clinician may choose to depart from these quantities, for example, based on the factors cited above and his expert opinion. In general, some guidance on the amounts to be administered can be obtained from the amounts normally administered for comparable conventional antibodies or antibody fragments against the same target, administered through essentially the same route, taking into account, however, the differences in affinity/avidity, efficacy, biodistribution, half-life and similar factors well known to the skilled person.
The mode of administration of a CTLA4 ligand (eg, ISVD as a Nanobody) to an individual can vary. Routes of administration include oral, rectal, transmucosal, intestinal, parenteral; intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, inhalation, insufflation, topical, cutaneous, transdermal, or intraarterial.
[00229] The determination of the appropriate dose is made by the clinician, for example, using parameters or factors known or suspected in the art to affect the treatment. In general, in dose determination, the dose starts with an amount slightly less than the ideal dose and is increased by small increments thereafter, until the desired or optimal effect is achieved relative to any negative side effects. Important diagnostic measurements include those of symptoms, for example, inflammation or level of inflammatory cytokines produced. In general, it is desirable that a biological agent that will be used be derived from the same species as the animal targeted for treatment, thus minimizing any immune response to the reagent. In the case of human subjects, for example, chimeric, humanized and fully human antibodies may be desirable. Guidance on the selection of suitable doses is available (see, for example, Wawrzynczak (1996) Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.) (1991) Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, NY;Bach (ed.) (1993) Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, NY;Baert et al (2003) New Engl.J.Med. 348:601 to 608; Milgrom et al (1999) New Engl J Med 341: 1,966 to 1973; Slamon et al (2001) New Engl J Med 344:783 to 792; Beniaminovitz et al (2000) New Engl. J. Med. 342:613 to 619; Ghosh et al. (2003) New Engl. J. Med. 348:24 to 32; Lipsky et al. (2000) New Engl. J. Med. 343: 1,594 to 1602) .
[00230] Whether a disease symptom has been alleviated can be assessed by any clinical measure typically used by physicians or other technical healthcare providers to assess the status of severity or progression of that symptom. Although an embodiment of the present invention (e.g., a method of treatment or article of manufacture) may not be effective in alleviating the target disease symptom (or symptoms) in all individuals, it should alleviate the symptom (or symptoms) of target disease in a statistically significant number of individuals, as determined by any statistical test known in the art, such as the Student's t-test, the chi2 test, the U-test according to Mann and Whitney, the Kruskal-Wallis test (test H), Jonckheere-Terpstra test and Wilcoxon test.
In general, the treatment regimen will be followed until the desired therapeutic effect is achieved and/or while the desired therapeutic effect is to be maintained. Again, this can be determined by the clinician.
[00232] As the CTLA4 ligands (e.g., ISVD as a Nanobody) of the present invention are able to bind CTLA4, they can be used, in particular, for the treatment or prevention of cancer, metastatic cancer, a solid tumor, a blood cancer, leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, cancer of prostate, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, squamous cell carcinoma, multiple myeloma, renal cell cancer, retinoblastoma , hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid kidney tumor, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, acoustic neuroma, a neuroectoderm tumor primitive mycus, medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelofibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer or liver cancer, breast cancer or gastric cancer.
The CTLA4 ligands (eg ISVD as a Nanobody) of the present invention can be used for the treatment or prevention of infectious diseases such as, for example, viral infection, bacterial infection, fungal infection or parasitic infection. In one embodiment of the invention, viral infection is infection with a virus selected from the group consisting of human immunodeficiency virus (HIV), Ebola virus, hepatitis virus (A, B, or C), herpes virus ( for example, VZV, HSV-I, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, or arboviral encephalitis virus. In one embodiment of the invention, bacterial infection is infection with a bacterium selected from the group consisting of Chlamydia, rickettsia bacteria, mycobacteria, staphylococcus, streptococcus, pneumonococcus, meningococcus and gonococcus, klebsiella, proteus, serratia, pseudomonas, Legionella, Corynebacterium diphtheriae, Salmonella, bacilli, Vibrio cholerae, Clostridium tetan, Clostridium botulinum, Bacillus anthricis, Yersinia pestis, Mycobacterium leprae, Mycobacterium lepromatosis and Borriella. In one embodiment of the invention, fungal infection is infection with a fungus selected from the group consisting of Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, apse, rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum. In one embodiment of the invention, the parasitic infection is infection with a parasite selected from the group consisting of Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba, Giardia lambia, Cryptosporidium, Pneumocystis carinii, Plasmodium vivax, Babesia microbruti, Trypanosoma brucei , Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Nippostrongylus brasiliensis.
The present invention also includes methods for:• preventing CTLA4-mediated inhibition of: co-stimulatory T cell signaling; T cell activation, T cell proliferation; • prevent CTLA4 binding to B7-1 (CD80) or B7-2 (CD86); and/or• enhance T cell activation
[00235] into the body of an individual by administering the CTLA4 ligand (for example, F023700912 or F023700914) to the individual; or in vitro by putting CTLA4 in contact with the CTLA4 ligand. Such activities can be mediated through the CTLA4 ligand. Thus, such methods can also be performed with any linker that includes a CTLA4 linker.
[00236] The invention also relates to methods of treating the aforementioned diseases and disorders, which, in general, comprise administering to an individual in need of such treatment (i.e., suffering from one of the aforementioned diseases) a therapeutically amount. of a CTLA4 ligand (e.g., ISVD as a Nanobody) of the invention. The invention also relates to a CTLA4 ligand of the invention for use in preventing or treating one of the aforementioned diseases or disorders.
[00237] The present invention also provides an injection device comprising any of the CTLA4 ligands (eg ISVD as a Nanobody), polypeptides or polynucleotides disclosed herein or a pharmaceutical composition thereof. An injection device is a device that introduces a substance into a patient's body via a parenteral route, for example, intramuscularly, subcutaneously or intravenously. For example, an injection device may be a syringe (e.g., pre-filled with the pharmaceutical composition, such as an autoinjector) that, for example, includes a cylinder or barrel for holding the fluid to be injected (e.g. the CTLA4 ligand or a pharmaceutical composition thereof), a needle for piercing the skin and/or blood vessels for fluid injection; and a plunger for pushing fluid out of the cylinder and through the needle hole. In one embodiment of the invention, an injection device comprising a CTLA4 ligand or a pharmaceutical composition thereof is an intravenous (IV) injection device. Such a device includes the CTLA4 ligand or a pharmaceutical composition thereof in a cannula or trocar/needle that can be attached to a tube that can be attached to a bag or reservoir to retain fluid (eg, saline; or Ringer's solution). lactate which comprises NaCl, sodium lactate, KCl, CaCl2e which optionally includes glucose) introduced into the subject's body through the cannula or trocar/needle. CTLA4 ligand or a pharmaceutical composition thereof can be, in one embodiment of the invention, introduced into the device once the trocar and cannula are inserted into a subject's vein and the trocar is removed from the inserted cannula. The IV device can be, for example, inserted into a peripheral vein (eg, in the hand or arm); in the superior vena cava or inferior vena cava, or within the right atrium of the heart (eg, a central IV); or into a subclavian, internal jugular, or femoral vein and, for example, advanced toward the heart until it reaches the superior vena cava or right atrium (eg, a central venous line). In one embodiment of the invention, an injection device is an autoinjector; a jet injector or an external infusion pump. A jet injection uses a narrow jet of high pressure liquid that penetrates the epidermis to introduce CTLA4 ligand or a pharmaceutical composition thereof to a patient's body. External infusion pumps are medical devices that deliver CTLA4 ligand or a pharmaceutical composition thereof into a patient's body in controlled amounts. External infusion pumps can be electrically or mechanically powered. Different pumps operate in different ways, for example, a syringe pump retains fluid in a syringe reservoir, and a movable piston controls fluid delivery, an elastomeric pump retains fluid in an extendable balloon reservoir, and the pressure from of the elastic walls of the balloon triggers fluid delivery. In a peristaltic pump, a set of cylinders squeeze a length of flexible tubing, pushing the fluid forward. In a multi-channel pump, fluids can be delivered from multiple reservoirs at multiple rates.
[00238] It should also be noted that the Figures, any Sequence Listing and the Experimental Part/Examples are given only to illustrate the invention and are not to be construed or construed as limiting the scope of the invention and/or the appended claims of any way, except where explicitly stated otherwise in this document.
[00239] Other aspects, modalities, advantages and applications of the invention will become evident from the additional description in this document.Examples
These examples are intended to exemplify the present invention and are not a limitation thereof. The compositions and methods set forth in the Examples form part of the present invention.Example 1: Binding of Nanobody F023700906 to CTLA-4-Fc
[00241] Monovalent 11F01 Nanobody F023700906 (L11V, A14P, Q45R, A74S, K83R, V89L, M96P, Q108L)-FLAG3-HIS6), a building block of F023700912, demonstrates binding to the CTLA-4-Fc fusion molecule a from being both human and cynomolgus ape. The rate constant for association, rate constant for dissociation and affinity were determined on a ProteOn XPR36 (BioRad 670BR0166) using human CTLA-4-hFc and cynomolgus monkey CTLA4-hFc (Table D below). These results demonstrate high affinity binding of the Nanobody to human and cynomolgus monkey CTLA-4, suggesting potential for the Nanobody to modulate CTLA-4 function and that the cynomolgus monkey can be used as a toxicology species. Table D-1. Binding of Nanobody to CTLA-4-Fc from Cynomolgus Monkey or Human

Example 2: Binding of F023700912 Nanobody to Cell Surface CTLA4
[00242] F023700912 demonstrates binding to human CTLA-4 expressed on cell surface. The connection of batches of F023700912 (11F01(E1D,L11V,A14P,Q45R,A74S,K83R,V89L,M96P,Q108L)- 35GS-11F01(L11V,A14P,Q45R,A74S,K83R,V89L,M96P,Q108L)-35GS - ALB11002-A]) (filled circles), F023700925 (PD1 binder-35GS- PD1 binder-35GS-11F01(L11 V,A14P,Q45R,A74S,K83R,V89L,M96P,Q108L)-35GS-11F01(L11V,A14P ,Q45R,A74S,K83R,V89L,M96P,Q108L)-35GS-ALB11002-A]) (filled squares) and an irrelevant Nb (filled triangles) a (A) c jurkat JE6.2.11 cells overexpressing hCTLA4 selected by volume or (B) CHO-K1 cells overexpressing hCTLA4 was studied by flow cytometry. Nanobodies were detected through mAB ABH0074 which binds to ALB11002. The data generated in these experiments are shown in Figure 5 (A-B). These results demonstrate the binding of F023700912 and F023700925 to CTLA-4 expressed on cell surface, suggesting that these Nanobodies modulate CTLA-4 function.
[00243] Figure 5 (AB) is a dilution series (1 μM initial concentration, 1/4 serial dilution, 12 pts) of Nbs lots F023700912 with extended half-life (building block ALB0011) (circles filled in), F023700925 (filled in squares) and negative control Nb IRR00051 (filled in triangles) in 200 μL of FACS buffer (PBS (Life Technologies, 14190-094), 10% heat-inactivated fetal bovine serum (Sigma, F7524), NaN3 at 0.05% (Thermo Scientific, 19038)) were added to (A) 2E4 JE6.2.11 jurkat cells overexpressing human CTLA4 selected by volume/well or (B) 2E4 CHO-K1 cells overexpressing human CTLA4/well and incubated for 30 minutes at 4°C.
[00244] After three washing steps (1 washing step = removal of Nb dilutions, addition of 100 µL of cold FACS buffer, centrifugation for 5 minutes at 250 g), the cells were incubated for 30 minutes at 4 °C with 3 μg/ml mouse anti-ALB11002 mAb ABH00074 in cold FACS buffer for detection of extended half-life Nanobodies.
After three washing steps, cells were incubated for 30 minutes at 4°C with a 1/100 dilution in cold FACS buffer of PE goat anti-mouse IgG F(ab')2 (Jackson ImmunoResearch, 115-116-071).
[00246] After three washing steps, cells were resuspended in 50 µL of cold FACS buffer supplemented with 5 nM TO-PRO-3 (Molecular Probes, T3605) and analyzed with a FACS Canto.
[00247] First, a P1 population is selected based on the FSC-SSC distribution. The stop record was set at 10,000 cells in P1. From this population, TO-PRO-3+ cells (dead cells) are excluded. For this TO-PRO-3/P1 negative population, the median PE value is calculated.Example 3: Nanobody F023700912 blocks CTLA-4 binding to CD80 and CD86
[00248] F023700912 blocks the binding of human CTLA-4 to its CD80 and CD86 ligands. Flow cytometry analysis of a competition experiment of F023700912 (filled circles) and ipilimumab (filled squares) with fixed concentrations (10 x EC30) of (A) hCD80-hFc or (B) hCD86-hFc in CHO-K1 cells that overexpress hCTLA4. Ligands were detected by the human IgG Fc fusion protein. The data generated in these experiments are shown in Figure 6 (A-B). These results demonstrate the ability of F023700912 to block the binding of CTLA-4 to its CD80 and CD86 ligands, illustrating the ability of F023700912 to affect the immune response modulated by CTLA-4 and its interactions with CD80 and CD86.
[00249] Figure 6 (AB) is a dilution series (1 μM initial concentration, 1/3 serial dilution, 12 pts) of Nb F023700912 (filled circles) and Ipilimumab (filled squares) in 100 μL of FACS buffer (PBS (Life Technologies, 14190-094), 10% heat-inactivated fetal bovine serum (Sigma, F7524), 0.05% NaN3 (ThermoScientific, 19038)) were added to 1E5 CHO-K1 cells overexpressing human CTLA4 /well in the presence of a fixed concentration of (A) FITC-labeled human CD80-hFc-HIS6 or (B) FITC-labeled human CD86-hFc-HIS6 (FITC identification was performed with an identification grade of 3.6 and 2, respectively; concentration = 10 x EC30, being 3.71E-08 M or 4.35E-08 M, respectively) and incubated for 90 minutes at 4 °C.
[00250] After three washing steps (1 washing step = removal of Nb dilutions, addition of 100 µL of cold FACS buffer, centrifugation for 5 minutes at 250 g), the cells were resuspended in 50 µl of supplemented cold FACS buffer with TO-PRO-3 at 5 nM (Molecular Probes, T3605) and analyzed with a FACS Canto.
[00251] First, a P1 population is selected based on the FSC-SSC distribution. The stop record was set at 10,000 cells in P1. From this population, TO-PRO-3+ cells (dead cells) are excluded. For this TO-PRO-3/P1 negative population, the median FITC value is calculated.Example 4: F023700912 Specificity Assessment
[00252] Specificity assessment of F023700912 demonstrated selective binding to CTLA-4. Specificity assessment against BTLA, CD8, PD1, CTLA4, LAG3, CD28 was performed on overexpressing cells using flow cytometry, while ICOS binding was assessed in ELISA as a recombinant protein (hICOS-hFc). The expression of BTLA, CD8, PD1, CTLA4, LAG3, CD28 was confirmed by directly labeled target-specific Abs. Anti-hlCOS and anti-hCTLA4 / anti-hPD1 positive controls were all positive. No binding to hICOS was observed in the ELISA assays. Figure 7 (AH) assesses binding to negative control L cells, negative control CHO-K1 cells, huCD28+ L cells, huCD8alpha+ L cells, huLag-3+ CHO-K1 cells, huBTLA+ CHO-K1 cells, huCTLA- cells 4+ CHO-K and huPD-1 + CHO-K1 cells, respectively. No binding to BTLA, CD8, PD1, LAG3, CD28 could be observed for F023700912, whereas potent binding of F023700912 was observed in CTLA-4+ CHO-K1 cells. The data generated in these experiments are shown in Figure 7 (A-H). These results illustrated the selective binding of F023700912 to CTLA-4, predicting minimal off-target effects under in vivo administration.
[00253] Figure 7 (AH) is a dilution series (1 μM initial concentration, 1/4 serial dilution, 12 pts) of Nbs lots F023700912 with extended half-life (building block ALB0011) (circles filled in), F023700925 (filled in squares) and negative control Nb IRR00051 (filled in triangles) in 200 μL of FACS buffer (PBS (Life Technologies, 14190-094), 10% heat-inactivated fetal bovine serum (Sigma, F7524), NaN3 at 0.05% (Thermo Scientific, 19038)) were added to (A) 2E4 L cells/well, (B) 2E4 CHO-K1/well cells, (C) L cells overexpressing human CD28 or (D) L cells which overexpress human CD8 alpha, (E) 2E4 CHO-K1 overexpress human LAG3/well, (F) 2E4 CHO-K1 cells overexpress human BTLA/well, (G) CHO-K1 cells overexpress human CTLA4/well or (H) CHO-K1 cells overexpressing human PD1/well and incubated for 30 minutes at 4°C.
[00254] After three washing steps (1 washing step = removal of Nb dilutions, addition of 100 µL of cold FACS buffer, centrifugation for 5 minutes at 250 g), the cells were incubated for 30 minutes at 4 °C with 3 μg/ml mouse anti-ALB0011 mAb ABH00074 in cold FACS buffer for detection of Nbs with extended half-life.
After three washing steps, cells were incubated for 30 minutes at 4°C with a 1/100 dilution in cold FACS buffer of PE goat anti-mouse IgG F(ab')2 (Jackson ImmunoResearch, 115-116-071).
[00256] After three washing steps, cells were resuspended in 50 µL of cold FACS buffer supplemented with 5 nM TO-PRO-3 (Molecular Probes, T3605) and analyzed with a FACS Canto.
[00257] First, a P1 population is selected based on the FSC-SSC distribution. The stop record was set at 10,000 cells in P1. From this population, TO-PRO-3+ cells (dead cells) are excluded. For this TO-PRO-3/P1 negative population, the median PE value is calculated.Example 5: F023700912 Nanobody Binding to Human, Rhesus Monkey and Mouse Albumin
[00258] F023700912 binds to human, rhesus monkey, and mouse albumin, predicting a prolonged half-life when compared to non-albumin-binding nanobodies. Binding to human, rhesus monkey and mouse serum albumin was observed when analyzed using surface plasmon resonance (SPR). The data are presented below in Table E. Albumin binding of F023700912 is expected to reduce Nanobody clearance upon in vivo administration, improving its therapeutic potential. Table E. Nanobody to Albumin Binding

[00259] Instrument: Biacore T100 (GE Healthcare); Sensor Chip: CM5 (ID T 160713 -2, GE Healthcare, lot 10242599) Example 6: N73 Nanobody Variants F023700906
[00260] The variants F023701051(11F01(L11V,A14P,Q45R,N73Q,A74S,K83R,V89L, M96P,Q108L)-FLAG3-HIS6), F023701054 (11F01(L11 V,A14P,Q45R,N73T,A74S,K83R, V89L,M96P,Q108L)-FLAG3-HIS6), and F023701061 (11F01(L11V,A14P,Q45R,N73Y, A74S,K83R,V89L,M96P,Q108L)-FLAG3-HIS6) were compared with F023700906 on their ability to block the binding of (A) CD80 or (B) CD86 to CHO-K1 cells expressing CTLA-4. All of these variants were able to block the binding of CD80 and CD84 to CTLA-4. Blocking of CTLA4 to CD80 and CD86 has been determined for several of the variants. These blocking data are shown in Figure 8 (A-B). These results illustrate the feasibility of amino acid variation at position N73 without major impact on the ability of Nanobodies to block the binding of CD80 or CD86 to CTLA-4. Such variants will allow avoiding deamidation in N73.Example 7: F023700912 eradicates established solid tumors in humanized mice
[00261] Humanized mice (Jackson Laboratories) were implanted with Panc 08.13 tumor cells (human pancreatic adenocarcinoma). Mice with established tumors (~100 mm3, n=9 to 10/group) were treated as follows: 1-isotype controls (hIgGl-2 mg/kg and hIgG4-3 mg/kg); 2-Ipilimumab-N297A (3 mg/kg); 3-Ipilimumab (3 mg/kg); 4-Pembrolizumab (2 mg/kg); 5-Ipilimumab (3 mg/kg) + Pembrolizumab (2 mg/kg); 6- F023700912 (5 mg/kg; indicated as CTLA4-Nab 5), 7- F023700912 (15 mg/kg; indicated as CTLA4-Nab-15) and 8-F023700912 (15 mg/kg) + Pembrolizumab (2 mg/kg kg). All antibodies were injected subcutaneously every 7 days for 6 doses. F023700912 was administered subcutaneously every 3.5 days for 11 doses. Tumor volume and body weight were measured every 4 to 5 days. Shown in Figure 9 (A-B) are mean ±SEM tumor volumes, individual tumor volumes at day 37, and individual mouse tumor volumes during the course of the experiment. Tumor volume for each treatment group is also shown in Figure 9 (C-J). Individual and mean body weight changes (mean ±SEM) in each treatment group were also measured (Figure 9 (k-s)). The number of mice that were found dead or humanely euthanized due to loss of body weight was indicated as "#". "Φ" indicated antibody and "*" indicated Nanobody dosing schedule. These data illustrated the ability of F023700912 to induce the human antitumor response in vivo in animals bearing human immune cells. These data reinforce the potential of F023700912 in the treatment of human cancer.Example 8: Binding of F023700912 and F023700925 to pre-existing antibodies from healthy individuals and cancer patients
[00262] The Trivalent Reference Nanobody, 013700112 (not modified to reduce binding of pre-existing antibodies) demonstrates binding to various serum samples derived from (Figure 10A) healthy individuals or (Figure 10B) cancer patients. The trivalent Nanobody with optimized sequence of similar size, F023700912, demonstrates a lower frequency of binding to the same serum samples. F023700925 comprises the same building blocks as F023700912. Despite the larger size, the pentavalent F023700925 Nanobody exhibits no more binding to pre-existing Abs than the reference Nanobody 013700112. The binding of pre-existing antibodies to Nanobodies captured in human serum albumin (HSA) was evaluated using ProteOn XPR36 (Bio-Rad Laboratories, Inc.). PBS/Tween (phosphate-buffered saline, pH 7.4, 0.005% Tween20) was used as the running buffer and the experiments were performed at 25 °C. The ligand strips from a ProteOn GLC sensor chip were activated with EDC/NHS (30 µL/min flow rate) and HSA was injected at 10 µg/mL in ProteOn acetate buffer pH 4.5 (flow rate of 30 µl/min). 100 µL/min) to produce immobilization levels of approximately 3600 RU. After immobilization, surfaces were deactivated with ethanolamine HCl (flow rate 30 μL/min). Nanobodies were injected for 2 minutes at 45 µL/min onto the HSA surface to produce a Nanobody capture level of approximately 600 RU for trivalent F023700912 and approximately 1000 RU for pentavalent F023700925. Samples containing pre-existing antibodies were diluted 1:10 in PBS-Tween20 (0.005%) before being injected for 2 minutes at 45 µL/min, followed by a subsequent 400-second dissociation step. After each cycle (ie, before a new blood sample injection and Nanobody capture step), the HSA surfaces were regenerated with a 2 minute injection of HCl (100 mM) at 45 µL/min. Sensorgram processing and data analysis were performed with ProteOn Manager 3.1.0 (Bio-Rad Laboratories, Inc.). Sensorgrams showing pre-existing antibody binding were obtained after double reference by subtracting 1) Nanobody-HSA dissociation and 2) non-specific binding to the reference linker band that contains only HSA. Pre-existing antibody binding levels were determined by setting reporting points at 125 seconds (5 seconds after the end of the association). As a reference, samples containing pre-existing antibodies were also tested for binding to an unmodified trivalent Nanobody to reduce binding of these pre-existing antibodies (T013700112).Example 9: Anti-hCTLA4 Nanobody Epitope Mapping by Spectrometry of hydrogen-deuterium exchange mass.
[00263] The contact areas between anti-hCTLA4 Nanobody, F023700912 were determined using deuterium-hydrogen exchange mass spectrometry (HDX-MS) analysis. HDX-MS measures the incorporation of deuterium into the protein's amide backbone and changes in this incorporation are influenced by hydrogen solvent exposure. A comparison was made between deuterium exchange levels in samples of antigen alone and samples bound to Nanobody to identify the regions of antigen that may be in contact with the Nanobody.
The human CTLA4 residues most strongly protected against deuteration by the Nanobody, F023700912 were VRVTVL (residues 33 to 38 of SEQ ID NO: 110), ADSQVTEVC (residues 41 to 49 of SEQ ID NO: 110) and CKVELMYPPPYYLG (residues 93 to 106 of SEQ ID NO: 110). A heat map to demonstrate F023700912 binding to CTLA4 is shown in Figure 13. Table F. Amino acid sequences (SEQ ID NO: 110)

权利要求:
Claims (22)
[0001]
1. CTLA4 ligand comprising one or more unique immunoglobulin variable domains (ISVDs) that bind to human CTLA4, characterized in that the ISVD comprises the amino acid sequence: XVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTY YADSVKGRGPSTISRQDNSKN (in XVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTY YADSVKGRGPSTISRQDNSKN YWGL in XVQLVESGGGVVQDNSKN ID NO: 60); optionally comprising a half-life extender and/or a C-terminal extender.
[0002]
2. CTLA4 ligand according to claim 1, characterized in that the ISVD comprises the amino acid sequence selected from SEQ ID NOs: 93 to 109; optionally devoid of the signal sequence (amino acids AAADYKDHDGDYKDHDIDYKDDDDKGAAHHHHHH (amino acids 120 to 153 of SEQ ID NO:93)) thereof.
[0003]
3. CTLA4 ligand according to claims 1 or 2, characterized in that it is fused to a half-life extender.
[0004]
4. CTLA4 ligand according to any one of claims 1 to 3, characterized in that the half-life extender is an ISVD that binds to human serum albumin.
[0005]
5. CTLA4 ligand according to claim 4, characterized in that the ISVD that binds to human serum albumin is ALB11002, which has the amino acid sequence shown in SEQ ID NO: 66.
[0006]
6. CTLA4 ligand according to claim 1 or 2, characterized in that it comprises: • an ISVD that binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 60, wherein X is D or E; • a peptide linker; • an ISVD that binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 60, where X is D or E; • a peptide linker; • a half-life extender; and, optionally, a C-terminally extending alanine.
[0007]
7. CTLA4 ligand according to claim 1 or 2, characterized in that it comprises: • an ISVD that binds to CTLA4 comprising the amino acid sequence shown in SEQ ID NO: 60, wherein X is D or E; • a peptide ligand; • a half-life extender; and, optionally, a C-terminally extending alanine.
[0008]
8. CTLA4 linker according to claim 6 or 7, characterized in that the peptide linker comprises the amino acid sequence GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 65).
[0009]
9. CTLA4 ligand according to any one of claims 1 to 8, characterized in that it comprises the amino acid sequence: DVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRT YYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTV SSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLR LSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRTYYADSVKGRFTISRDNSKNTV YLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTVSSGGGGSGGGGSGGGGSGG GGSGGGGSGGGGSGGGGSEVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQ APGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGG SLSRSSQGTLVTVSSA (SEQ ID NO: 62).
[0010]
10. CTLA4 ligand according to any one of claims 1 to 8, characterized in that it comprises the amino acid sequence: DVQLVESGGGVVQPGGSLRLSCAASGGTFSFYGMGWFRQAPGKEREFVADIRTSAGRT YYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAEPSGISGWDYWGQGTLVTV SSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVQPGNSLR LSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTL YLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSA (SEQ ID NO: 64).
[0011]
11. CTLA4 ligand according to claim 1 or 2, characterized in that it is multivalent.
[0012]
12. Ligand, characterized in that it cross-blocks a CTLA4 ligand defined in any one of claims 1 to 11 against binding to human CTLA4.
[0013]
13. Container or injection device, characterized in that it comprises the CTLA4 ligand defined in any one of claims 1 to 12, optionally in association with an additional therapeutic agent.
[0014]
14. Polynucleotide, characterized in that it encodes the CTLA4 ligand defined in any one of claims 1 to 12, wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO: 61 or 63.
[0015]
15. Vector, characterized in that it comprises the polynucleotide defined in claim 14.
[0016]
16. Host cell, characterized in that it comprises the polynucleotide defined in claim 14, or the vector defined in claim 15, wherein the host cell is a Pichia cell.
[0017]
17. Method for making the CTLA4 ligand defined in any one of claims 1 to 12, characterized in that it comprises introducing a polynucleotide encoding the CTLA4 ligand into a host cell and culturing the host cell in a medium under conditions favorable for expressing said CTLA4 linker from said polynucleotide and, optionally, purifying the CTLA4 linker from said host cell and/or said medium.
[0018]
18. Method to prevent CTLA4 from binding to CD80 or CD86, characterized in that it comprises placing CTLA4 in contact with the CTLA4 ligand defined in any one of claims 1 to 12, optionally in association with an additional therapeutic agent.
[0019]
19. Use of the CTLA4 ligand defined in any one of claims 1 to 12 and, optionally, of an additional therapeutic agent, characterized in that it is for the manufacture of a single pharmaceutical composition or two or more pharmaceutical compositions to increase an immune response in an individual's body.
[0020]
20. Use of the CTLA4 ligand defined in any one of claims 1 to 12 and, optionally, of an additional therapeutic agent, characterized in that it is for the manufacture of a single pharmaceutical composition or two or more pharmaceutical compositions to treat or prevent cancer or an infectious disease in the body of a human individual.
[0021]
21. Use according to claim 20, characterized in that the cancer is metastatic cancer, a solid tumor, a hematological cancer, leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer , bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma , head and neck cancer, squamous cell carcinoma, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid kidney tumor, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma , acoustic neuroma, a primitive neuroectodermal tumor, medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia ver a, thrombocythemia, idiopathic myelofibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer or liver cancer, breast cancer or gastric cancer.
[0022]
22. Use according to claim 20, characterized in that the infectious disease is a bacterial infection, a viral infection or a fungal infection.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US11155619B2|2021-10-26|PD1 and/or LAG3 binders

---

US10544222B2|2020-01-28|PD1/CTLA4 binders

---

BR112018009972B1|2021-08-24|CTLA4 LIGAND, LINKER, CONTAINER OR INJECTION DEVICE, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHODS FOR MAKING CTLA4 LIGAND AND TO PREVENT CTLA4 FROM CONNECTING TO CD80 OR CD86 AND USES OF SUCH CTLA4 LIGAND

---

US20190177414A1|2019-06-13|Anti-ctla4 antibodies

---

TW201809006A|2018-03-16|Anti-PD-1 antibodies

---

TWI754622B|2022-02-11|Ctla4 binders

---

TWI754621B|2022-02-11|Pd1 and/or lag3 binders

同族专利:

---

公开号 | 公开日

---

GEP20207174B|2020-11-10|

---

CN108473565A|2018-08-31|

---

TN2018000169A1|2019-10-04|

---

CL2018001326A1|2018-10-12|

---

WO2017087588A1|2017-05-26|

---

KR20180070712A|2018-06-26|

---

US20200157220A1|2020-05-21|

---

KR102095140B1|2020-03-31|

---

AU2016355569A1|2018-05-17|

---

ECSP18045497A|2018-07-31|

---

MA43259A|2018-09-26|

---

MX2018006246A|2018-08-01|

---

SG11201804127SA|2018-06-28|

---

HK1254952A1|2019-08-02|

---

AU2016355569B2|2020-01-02|

---

DOP2018000125A|2018-09-30|

---

SV2018005693A|2019-01-18|

---

CA3004900A1|2017-05-26|

---

CR20180279A|2018-08-24|

---

EA201891166A1|2018-11-30|

---

GEAP201614811A|2020-07-10|

---

CA3004900C|2021-08-10|

---

EA038179B1|2021-07-20|

---

JP2019503655A|2019-02-14|

---

NI201800062A|2018-07-24|

---

US10501542B2|2019-12-10|

---

PH12018501079A1|2019-01-28|

---

JP6768800B2|2020-10-14|

---

JO3739B1|2021-01-31|

---

IL259173D0|2018-06-28|

---

CO2018005161A2|2018-11-30|

---

US20170137521A1|2017-05-18|

---

AR106753A1|2018-02-14|

---

BR112018009972A2|2018-11-13|

---

TW201726741A|2017-08-01|

---

EP3377527A1|2018-09-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB2183662B|1985-04-01|1989-01-25|Celltech Ltd|Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same|

---

GB8601597D0|1986-01-23|1986-02-26|Wilson R H|Nucleotide sequences|

---

GB8717430D0|1987-07-23|1987-08-26|Celltech Ltd|Recombinant dna product|

---

GB8809129D0|1988-04-18|1988-05-18|Celltech Ltd|Recombinant dna methods vectors and host cells|

---

US5859205A|1989-12-21|1999-01-12|Celltech Limited|Humanised antibodies|

---

US5397703A|1992-07-09|1995-03-14|Cetus Oncology Corporation|Method for generation of antibodies to cell surface molecules|

---

CA2142331C|1992-08-21|2010-02-02|Cecile Casterman|Immunoglobulins devoid of light chains|

---

EP0663007A1|1992-09-29|1995-07-19|The President And Fellows Of Harvard College|Trophic factor having ion channel-inducing activity in neuronal cells|

---

US6824779B1|1993-07-26|2004-11-30|Dana-Farber Cancer Institute, Inc.|Methods for inhibiting the interaction of B7-2 with its natural ligand|

---

EP0739981A1|1995-04-25|1996-10-30|Vrije Universiteit Brussel|Variable fragments of immunoglobulins -use for therapeutic or veterinary purposes|

---

US6670453B2|1997-10-27|2003-12-30|Unilever Patent Holdings B.V.|Multivalent antigen-binding proteins|

---

EP2270147B2|1999-04-09|2020-07-22|Kyowa Kirin Co., Ltd.|Method for controlling the activity of immunologically functional molecule|

---

US20020006403A1|1999-12-14|2002-01-17|Xue-Zhong Yu|CD28-specific antibody compositions for use in methods of immunosuppression|

---

US7795002B2|2000-06-28|2010-09-14|Glycofi, Inc.|Production of galactosylated glycoproteins in lower eukaryotes|

---

AU9696201A|2000-09-29|2002-04-08|Schering Corp|Pegylated interleukin-10|

---

US6946292B2|2000-10-06|2005-09-20|Kyowa Hakko Kogyo Co., Ltd.|Cells producing antibody compositions with increased antibody dependent cytotoxic activity|

---

AT477275T|2000-12-26|2010-08-15|Inst Nat Sante Rech Med|ANTIBODIES AGAINST CD28|

---

US9321832B2|2002-06-28|2016-04-26|Domantis Limited|Ligand|

---

US20060002935A1|2002-06-28|2006-01-05|Domantis Limited|Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor|

---

JP4488740B2|2001-11-13|2010-06-23|ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド|Agents that modulate immune cell activation and methods of use thereof|

---

EP2390268B1|2002-11-08|2017-11-01|Ablynx N.V.|Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor|

---

ES2542330T3|2003-01-10|2015-08-04|Ablynx N.V.|Therapeutic polypeptides, homologs thereof, fragments thereof and their use in modulating platelet-mediated aggregation|

---

PT1687338E|2003-11-07|2011-01-20|Ablynx Nv|Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof|

---

EP1863847A2|2004-12-02|2007-12-12|Domantis Limited|Anti-il-1r1 single domain antibodies and therapeutic uses|

---

US20080107601A1|2004-10-13|2008-05-08|Ablynx N.V.|Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease|

---

PT2949668T|2005-05-18|2019-10-24|Ablynx Nv|Improved nanobodies tm against tumor necrosis factor-alpha|

---

DK2444424T3|2005-05-20|2018-12-03|Ablynx Nv|IMPROVED NANOL BODIES FOR TREATING AGGREGATED MEDICINAL DISORDERS|

---

WO2007063308A2|2005-12-01|2007-06-07|Domantis Limited|Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1|

---

EA200801166A1|2005-12-01|2008-12-30|Домантис Лимитед|FORMATS OF COMPETITIVE DOMAIN ANTIBODIES THAT ARE ASSOCIATED WITH INTERLEUKIN RECEPTOR FIRST TYPE 1|

---

US20100047171A1|2006-01-24|2010-02-25|Roland Beckmann|Fusion Proteins That Contain Natural Junctions|

---

FR2894741B1|2005-12-08|2009-12-04|Centre Nat Etd Spatiales|SATELLITE RECEPTION CHAIN|

---

JP2010500876A|2006-08-18|2010-01-14|アブリンクスエン．ヴェー．|Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling|

---

EP2097449A1|2006-12-05|2009-09-09|Ablynx N.V.|Peptides capable of binding to serum proteins|

---

WO2008071447A2|2006-12-15|2008-06-19|Ablynx N.V.|Amino acid sequences that modulate the interaction between cells of the immune system|

---

KR101264473B1|2007-05-24|2013-05-29|아블린쓰 엔.브이.|Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders|

---

MX2010005783A|2007-11-27|2010-08-10|Ablynx Nv|Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.|

---

AU2009248049B2|2008-05-16|2015-07-23|Ablynx N.V.|Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same|

---

EP2315778A2|2008-07-18|2011-05-04|Domantis Limited|Compositions monovalent for cd28 binding and methods of use|

---

KR20120038494A|2009-07-16|2012-04-23|글락소 그룹 리미티드|Improved anti-serum albumin binding single variable domains|

---

CA3142288A1|2011-06-23|2012-12-27|Ablynx Nv|Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains|

---

SI2723771T1|2011-06-23|2019-12-31|Ablynx Nv|Serum albumin binding proteins|

---

EP2744822B1|2011-08-17|2020-06-24|Glaxo Group Limited|Modified proteins and peptides|

---

WO2013066765A1|2011-11-01|2013-05-10|Merck Sharp & Dohme Corp.|Mutation of tup1 in glycoengineered yeast|

---

EP2895510A2|2012-09-13|2015-07-22|Novartis AG|Single domain antibody with c-terminal modification|

---

WO2014111550A1|2013-01-17|2014-07-24|Glaxosmithkline Intellectual Property Development Limited|Modified anti-serum albumin binding proteins|

---

US20160251440A1|2013-09-26|2016-09-01|Ablynx N.V.|Bispecific nanobodies|

---

KR20170002645A|2014-05-16|2017-01-06|아블린쓰 엔.브이.|Improved immunoglobulin variable domains|

---

HUE050007T2|2014-05-16|2020-11-30|Ablynx Nv|Immunoglobulin variable domains|

---

RU2755724C2|2015-11-18|2021-09-20|Мерк Шарп И Доум Корп.|Pd1/ctla4-binding substances|

---

CA3004748C|2015-11-18|2021-11-16|Merck Sharp & Dohme Corp.|Pd1 and/or lag3 binders|WO2008156712A1|2007-06-18|2008-12-24|N. V. Organon|Antibodies to human programmed death receptor pd-1|

---

CA3142288A1|2011-06-23|2012-12-27|Ablynx Nv|Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains|

---

KR20170002645A|2014-05-16|2017-01-06|아블린쓰 엔.브이.|Improved immunoglobulin variable domains|

---

CA3004748C|2015-11-18|2021-11-16|Merck Sharp & Dohme Corp.|Pd1 and/or lag3 binders|

---

EP3471754A1|2016-06-20|2019-04-24|Kymab Limited|Anti-pd-l1 antibodies|

---

EP3768721A4|2018-03-19|2021-12-29|Wuxi Biologics Ireland Limited.|Novel anti-ctla-4 antibody polypeptide|

---

SG11202101982RA|2018-09-26|2021-03-30|Ascendis Pharma As|Degradable hyaluronic acid hydrogels|

---

EP3898677A1|2018-12-21|2021-10-27|OSE Immunotherapeutics|Bifunctional anti-pd-1/il-7 molecule|

---

WO2020165374A1|2019-02-14|2020-08-20|Ose Immunotherapeutics|Bifunctional molecule comprising il-15ra|

---

CN110950957B|2019-12-13|2022-03-08|源道隆（苏州）医学科技有限公司|Polypeptide capable of binding CTLA4 and application thereof|

---

TW202136287A|2019-12-17|2021-10-01|法商Ｏｓｅ免疫治療公司|Bifunctional molecules comprising an il-7 variant|

---

CN113121689A|2020-01-16|2021-07-16|三优生物医药有限公司|CTLA-4 binding molecules and uses thereof|

法律状态:
2019-10-15| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-03-10| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-03-09| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-03-16| B07B| Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2618 DE 09/03/2021 POR TER SIDO INDEVIDA. |

---

2021-03-23| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-07-20| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-08-24| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2016, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201562257001P| true| 2015-11-18|2015-11-18|

---

US62/257,001|2015-11-18|

---

PCT/US2016/062393|WO2017087588A1|2015-11-18|2016-11-17|Ctla4 binders|

---